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Hormone replacement therapy (HRT) is usually prescribed to 
postmenopausal women suffering from menopausal symptoms such as hot 
flushes, vaginal atrophy, reduced sexual function and depression. However, 
according to Women Health Initiative from United States National Institute of 
Health (US NIH), the use of HRT is associated with 26% increase in breast 
cancer risk. On the other hand, epidemiological evidence suggests that 
phytoestrogen might be beneficial for alleviating menopausal symptoms 
without increasing the risk of breast cancer. As such, we have chosen to study 
icaritin, a phytoestrogen derived from Herba Epimedii. Herba Epimedii is a 
medicinal herbal plant traditionally prescribed for improving bone health, 
amongst other indications. Since 17β‐estradiol (estradiol) is naturally present 
in the body even after menopause, the combinatorial effect estradiol and 
icaritin has relevance to the use of these compounds in subjects at risk of or 
suffering from breast cancer. Hence, as the initial step, we performed in vitro 
study to test the combinatorial effects icaritin and estradiol on MCF-7 breast 
cancer cell. 
Icaritin increased MCF-7 breast cancer cell proliferation at doses less 
than 10 µM. However, the combination of 1 µM of icaritin with 100 pM 
estradiol inhibited the cell growth induced by estradiol. Estradiol/icaritin 
combination also induced lower estrogen receptor (ER)-regulated promoter 
activity and decreased GREB1 (growth regulation by estrogen in breast cancer 
1) mRNA level compared to either ligand alone.   
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As we were interested to investigate the molecular basis for this effect, 
we used a bioinformatics approach to fish for genes that are differentially 
regulated by icaritin. Microarray analyses directed our attention to CYP1A1 
gene, an AhR-regulated gene. Independent quantitative real-time PCR 
experiments confirmed that icaritin induced CYP1A1 and the AhR-regulated 
XRE promoter, linking icaritin to the AhR-regulated signaling pathways. 
Knockdown of AhR blocked the profound degradation of ERα induced by 
estradiol/icaritin combination, indicating the central role of icaritin on AhR-
mediated receptor stability. In contrast, knockdown of AhR gene did not 
restore estradiol-mediated degradation of ERα, consistent with the fact that 
estradiol is not a ligand for AhR. AhR knockdown blocked suppressive effects 
of icaritin on estradiol-stimulated breast cancer cell proliferation and GREB1 
gene expression. Our study indicates that icaritin can modulate estradiol-
stimulated MCF-7 cell proliferation via AhR-mediated proteasomal 
degradation of ERα to decrease GREB1 mRNA level.  
In conclusion, the concurrent use of icaritin with estradiol reduces 
estradiol-stimulated MCF-7 cell growth in vitro via activation of AhR-E3 
ubiquitin ligase pathway. Based on the in vitro study, icaritin might be further 
developed as a drug to be co-administered with HRT to reduce breast cancer 
risk caused by HRT.  
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CHAPTER 1 INTRODUCTION 
1.1 Breast cancer 
Breast cancer is currently the most prevalent malignancy among 
women in developed societies. According to World Health Organisation’s Fact 
sheet N°297 published in February 2009, breast cancer is one of the top five 
leading causes of deaths worldwide (519 000 deaths, 2004). It is ranked as the 
most frequent type of cancer causing death in women worldwide. In the local 
context, according to Singapore Cancer Registry, Interim Report entitled 
Trends in Cancer Incidence in Singapore 2003-2007, breast cancer is the 
number one cancer affecting local Singapore women with 6798 sufferers. It is 
a health burden worldwide, affecting women from high to low-resource 
settings. Despite the availability of therapies targeting estrogen and growth 
factor signaling pathways, the incidence and mortality of breast cancers have 
not decline at the same rate as other major causes of death, highlighting the 
need for new therapeutics strategies. Notably, majority of breast cancers 
express the estrogen receptor (ERα), a member of the nuclear receptor (NR) 
superfamily of ligand-inducible transcription factors, and thus respond to 
mitogenic actions of estrogen(s).   
Studies on cancer cases in the five continents of the world have shown 
that there are at least 10-fold variation in the occurrence of breast cancer 
worldwide (Parkin et al, 1992), most probably due to differences in socio-
economic status  giving rise to reproductive, hormonal and nutritional factors. 
The highest incidence rates occur in northern Europe, northern America, 
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Australia and New Zealand, and in the southern countries of South America, 
especially Uruguay and Argentina (Bray et al, 2004). Incidences is low 
throughout Asia, Africa and most of the Central and South America (Bray et 
al, 2004).  
Breast cancer incidence shows a distinctive age-specific curve, with 
rapid increase before menopause (40 - 50 years old). The rate slows down 
thereafter, most likely due to the decrease in estrogen level due to start of 
menopause (Bray et al, 2004). The duration of exposure to endogenous 
ovarian hormones might be related to breast cancer risk, with a year delay in 
the onset of menarche associated with 5% reduction of breast cancer risk 
(Hunter et al, 1997).    
 
1.1.1 Risk factors for breast cancer 
In general, the population lifetime risk of being diagnosed with breast 
cancer is one in eight to one in twelve (Amir et al, 2010). Risk factors such as 
use of hormone replacement therapy (HRT), reproductive history and 
hormonal contraceptive use can substantially modify the risk of developing 
breast cancer.  
Hormone replacement therapy (HRT) is one of the most commonly 
prescribed drug regimens given to postmenopausal women to alleviate the 
menopausal symptoms such as hot flushes, depression, mood swings and 
sleeping disorders. However, recently, the dissemination of results from the 
Women’s Health Initiative (WHI) clinical trial in 2002 brought to light the 
risks associated with use of HRT and increased risk of breast cancer. 
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According to the study, the use of HRT is associated with 26% increase in 
breast cancer risk. Another study, observational Million Women Study (MWS) 
found that the risk of breast cancer increases with duration of HRT use. Ten 
years' use of HRT is estimated to result in five additional breast cancers per 
1000 users of estrogen-only preparations and 19 additional cancers per 1000 
users of oestrogen-progestagen combinations.  
Women who had first pregnancy at an early age are observed to have 
lower incidence of breast cancer. This is probably due to the longer breast-
feeding duration exerting protective effect against breast cancer (Beral, 2003). 
A study done by Collaborative Group on Hormonal Factors in Breast Cancer 
found that the risk of breast cancer decreased with the number of child births. 
Each child birth decreased the risk of breast cancer by approximately 7%. 
However, this birth related decrease in breast cancer risk is dependent on the 
age of first child birth. Women who have their first child before 20 years old 
shows a 30% decrease in risk than women with who give birth to their first 
child after the age of 35 (Kabuto et al, 2000). 
In 1996, the Collaborative Group on Hormonal Factors in Breast 
Cancer conducted a study to investigate the association between hormonal 
contraceptives use and breast cancer. From the study, it was concluded that 
contraceptive usage is associated with slightly higher risk of breast cancer. 
Nevertheless, there is no evidence of significant excess risk of breast cancer 
diagnosed due to prolong use (> 10 years) of oral contraceptive pills. The issue 
is debatable, partly due to the changing formulations in the contraceptives 
(Hankinson et al, 1997; Kumle et al, 2002; Magnusson et al, 1999; 
Marchbanks et al, 2002).  




1.2.1 Physiological roles of estrogens 
Estrogens are pivotal hormones in the progression of the majority of 
human breast cancers. Estrogens influence growth, differentiation and function 
of tissues of the female reproductive system, i.e., uterus, ovary, and breast as 
well as non-reproductive tissues such as bone and cardiovascular system. The 
effects of estrogens in tissues are mediated by ERα and ERβ, expressed to 
varying extent in most organs, including uterus, ovary, breast, brain, lung, 
liver, prostrate, testis and kidney. Most early stage mammary tumors are ER 
positive and are responsive to endocrine therapies which target ERα and/or 
estradiol biosynthesis. 
There are three forms of estrogen, namely 17β-estradiol (estradiol), 
estrone (E1) and estriol (E3). However, the most prevalent form of human 
estrogen is estradiol. Estrogens are produced and secreted by the theca and 
granulose cells of the ovaries. The biological actions of estrogens are regulated 
by their concentration in the circulation, the intracellular conversion into more 
or less active derivatives and the ER concentration in the target tissues. The 
source of circulating estrogens in premenopausal women is predominantly the 
ovary and uptake of hormone from circulation is the primary mechanism for 
maintenance of estradiol concentration in breast cancer tissues. This situation 
changes drastically in postmenopausal women. Menopause is a naturally 
occurring physiological condition in every woman with an average age of 
onset at 51 years old. It is a permanent cessation of menstruation due to loss of 
ovarian follicular function. The symptoms include hot flushes, vaginal atrophy, 
reduced sexual function and depression. The syndromes include coronary 
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heart disease and osteoporosis. To alleviate these symptoms, the women are 
given hormone replacement therapy (HRT) which is combination of 
conjugated equine estrogen and medroxyprogesterone acetate. HRT is able to 
increase estradiol levels in postmenopausal women from < 36 pM to 100 pM 
(Table 1.1 and Table 1.2) (Nelson et al, 2004; Yasui et al, 2005). However, 
studies from US NIH (Women Health Initiative) indicated that HRT in 
menopausal women is associated with 26% increase in breast cancer risk. On 
top of that, data suggest that use of HRT in breast cancer survivors may 
increase the chance of breast cancer recurrence (Table 1.3) (Holmberg et al, 
2004; Holmberg et al, 2008; Marsden et al, 2000; von Schoultz et al, 2005). 
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Table 1.1 Reference intervals for estrone and estradiol in adult males, pre- and 
postmenopausal females. [Figure adapted from (Nelson et al, 2004)]. 
   N Estrone, (pM) Estradiol (pM)
Adult males 32 37 to 200 36 to 147 
Premenopausal females 92 62 to 740 55 to 1280 
Postmenopausal females 30 25 to 148 <36 
 
Table 1.2 Serum estrone and estradiol levels in postmenopausal women 
receiving HRT every other day and every day. Serum estrogen levels are 
measured in 84 postmenopausal women (HRT every day: 38 women; HRT 
every other day: 46 women). Fasting blood samples were drawn 12–18 hours 
after HRT. [Figure adapted from (Yasui et al, 2005)]. 
 
 
  Means + S.D 
  Estrone (pM) Estradiol (pM)
Before HRT every day 75.1+ 38.8  19.5+ 15.1 
Before HRT every other day 57.7 + 30.0 17.6 + 13.6 
After HRT every day 665.5 + 276.6 115.4 + 29.4 
After HRT every other day  270.0 + 138 52.5 + 12.8  
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Table 1.3 Randomized controlled trials to test the effect of estrogen plus 
progestin therapy in postmenopausal hormone therapy and recurrence of 
breast cancer. Table shows the risk of breast cancer recurrence in breast cancer 
survivors after hormone replacement therapy. [Figure adapted from 
(Holmberg et al, 2004; Holmberg et al, 2008; Marsden et al, 2000; von 
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1.2.2 Metabolism of estrogens 
Estrogens are metabolized by sulfation or glucuronidation and the 
conjugates are excreted into the bile or urine. Hydrolysis of these conjugates 
by the intestinal flora and subsequent re-absorption of the estrogen result in an 
enterohepatic circulation of estrogen. Estrogens are also metabolized by 
hydroxylation and subsequent methylation to form catechol and methoxylated 
estrogens (Osawa et al, 1993). Hydroxylation of estrogens yields 2-
hydroxyestrogens, 4-hydroxyestrogens and 16α-hydroxyestrogens (catechol 
estrogens). 4-hydroxyestrone and 16α-hydroxyestradiol are carcinogenic.  
 
1.2.3 Estrogens and mammary gland 
Estrogens are necessary for normal development, induction and 
progression of mammary carcinoma. Mitogenic actions of estrogens are 
critical in the etiology and progression of human breast and gynaecologic 
cancers. Some breast cancers are responsive to estrogens for growth. 
Estrogens directly increased the growth of breast cancer cells in culture by 
increasing the number of G0/G1 cells entering into the cell cycle (Doisneau-
Sixou et al, 2003). Although estrogens play important roles in the initiation 
and development of breast cancer, the exact mechanism(s) by which estrogens 
regulate mammary epithelial cell proliferation is not well defined.     
When estrogen molecules circulate in the bloodstream and move 
throughout the body, they exert effects only on cells with ERs. Tissues that 
express ERs include mammary gland, uterus, vagina, ovary, testes, epididymis 
and prostate (Conneely, 2001; Pettersson et al, 2001).  
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1.3 Estrogen receptors 
 There are two forms of ER, ie ERα and ERβ. Both ERα and ERβ are 
members of the steroid receptor super family of nuclear transcription factors 
(Mangelsdorf et al, 1995). ERβ is expressed mainly in human tissues such as 
the central nervous system, gastrointestinal tract, kidneys and lungs (Omoto et 
al, 2001). In contrast, ERα seems to predominate in reproductive tissues such 
as the uterus and breast, although a small amount of ERβ is also present in 
these tissues. In tissues where both ERα and ERβ are co-expressed, it has been 
found that ERβ opposes ERα’s action. Hence, the estrogen action in tissues 
where both receptors are co-expressed is very complex (Nilsson et al, 2001).  
 
1.3.1 Structure of ERα and ERβ 
The human ERα transcript encodes a protein of 595 amino acids with 
an approximate molecular mass of 66 kDa (Green et al, 1986; Walter et al, 
1985) and this gene is mapped to chromosome 6 (Menasce et al, 1993). The 
human ERβ is slightly smaller than the ERα, composed of 485 amino acids 
and with estimated molecular mass of 55 kDa (Kuiper et al, 1996). In common 
with other members of the steroid receptor super family, ERs are organized 
into six domains (A – F) that are responsible for specific functions (Greschik 
et al, 2003; Katzenellenbogen et al, 1996; Robinson-Rechavi et al, 2003) 
(Figure 1.1). The N-terminal transactivation domain (TAD) has a ligand-
independent activation function. The DNA-binding domain (DBD) enables 
receptor binding to estrogen response element (ERE). The DBDs of ERα and 
ERβ share approximately 97% sequence homology but significant differences 
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in amino-acid sequences are found in the N-terminal and ligand-binding 
domains. Both ERα and ERβ bind to ERE in promoter regions of target cells. 
In addition, ERs regulate AP-1 enhancer elements by acting on the 
transcription factors Fos and Jun. The ligand-binding domain (LBD) also 
harbors a nuclear localization signal as well as sequences necessary for 
dimerization and transcriptional activation.  
 
 
Figure 1.1 Schematic drawing of steroid hormone receptors. Estrogen 
receptor α (ERα) and estrogen receptor β (ERβ). (A and B) variable N-
terminal region (C) conserved DNA binding domain, (D) variable hinge 
region, (E) conserved ligand binding domain and (F) variable C-terminal 
region. [Figure taken from (Beck et al, 2005)]. 
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1.3.2 ER signaling 
  The most well-characterized estrogen receptor signaling occurs via 
cellular genomic response where lipophilic ligands diffuse through the cellular 
membrane, bind to ER, induce conformational change and release inhibitory 
heat shock protein (hsp) (Chambraud et al, 1990; Redeuilh et al, 1987). This 
unveils nuclear localization signal (NLS), allowing ligand bound receptor 
dimer translocation into the nucleus resulting in transcriptional regulation of 
target genes. Besides genomic pathway, estrogen signaling can also be 
mediated through non-genomic pathways, specifically via phosphorylation at 
S-118. This mechanism can be hormone-dependent or hormone-independent.  
 
1.3.3 Co-activators and co-repressors of ER 
 Upon ligand binding, ERα undergoes a major conformational change, 
recruits co-activator or co-repressor molecules to its cognate DNA response 
element located in the promoter/enhancer elements of target genes, thereby 
initiating transcription of genes that regulates the growth of breast cancer cells, 
i.e. growth regulation by estrogen in breast cancer 1 (GREB1).  With more 
than 300 co-regulators identified (Lonard et al, 2007), ERα-mediated 
transcription is a highly regulated process, involving a multitude of co-
regulatory factors, signaling pathways and is also critically dependent on the 
stability of ERα receptor protein. 
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1.3.4 Proteasome-dependent degradation of ERα protein 
Estrogen receptor is important in promoting growth and progression of 
breast cancer cells. Hence, there is great interest in exploring ways to 
functionally inactivate the estrogen receptor (ER), thereby suppressing the ER-
mediated gene expression and cell proliferation. These approaches include the 
use of anti-estrogens which binds competitively to the ERα and block the 
activation of the receptor. The second approach is to target proteasomal 
degradation of ERα mediated primarily by ubiquitin-proteasome pathway 
(Nawaz et al, 1999).  
Ligand-bound ERα is demonstrated to be covalently conjugated with 
ubiquitin in vitro (Nawaz et al, 1999) and in vivo (McDonnell et al, 2002; 
Nawaz et al, 1999), thus targeting it for protein degradation. This process 
involves addition of ubiquitin by a series of enzymes, i.e. E1 ubiquitin-
activating enzymes (Uba), E2 ubiquitin-conjugating enzymes (Ubc) and E3 
ubiquitin ligases (Reid et al, 2003). Protein targeting specificity relies on the 
unique interaction between a particular combination of an E2 (of which there 
are relatively few), an E3 (of which there are many) and target protein 
(Robinson et al, 2004). There are two major types of E3s in eukaryotes, 
defined by the presence of either a HECT or a RING domain. HECT ubiquitin 
ligases interact with target protein, resulting in transfer of ubiquitin. An 
example of E3 ubiquitin ligase with HECT domain is E6-associated protein 
(E6-AP). Ubiquitin ligases with RING domain does not interact with target 
protein but facilitates the interaction between target protein and E2 ligase 
(Robinson et al, 2004). E3 ligase of this type includes inhibitor of apoptosis 
proteins (IAPs) and murine double minute-2 (MDM2) (Robinson et al, 2004).  
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Estradiol binding accelerates ERα degradation, reducing the half life of 
ERα from 5 days to 3-4 hours. Ubiquitin ligases identified as components of 
the estradiol-ERα degradation system include subunits of the cullin RING 
ubiquitin ligase superfamily such as MDM2, E6-AP (Shao et al, 2004) and 
BRCA1. Pure antagonist fulvestrant, also known as ICI 182, 780 and marketed 
by AstraZeneca as Faslodex, inhibits ERα activity by inducing rapid 
downregulation of the receptor. In contrast, tamoxifen stabilized the receptor, 
leading to hormone resistance and tamoxifen-activated mutant cancers. 
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1.4 Selective estrogen receptor modulators (SERMs) and 
treatment of breast cancer 
1.4.1 Breast cancer treatments 
 One of the most prevalent characteristics of breast cancer proliferation 
is hormonal control of its growth, making estrogen or estrogen receptor 
targeted pathways for breast cancer therapy. Estrogen receptor (ER) has been 
detected in more than half of the human breast cancer cases, with 70% of these 
ER-positive tumors responding to endocrine therapy (Allegra et al, 1980; 
Osborne et al, 1980; Paridaens et al, 1980; Saceda et al, 1988).  
The hormonal systemic therapy of ERα positive breast cancer is 
targeted at two major pathways 1) blocking the synthesis of estradiol using 
aromatase inhibitors (exemestane, anastrozole or letrozole) or 2) competitive 
inhibition of the receptor activity using selective ER modulators (SERMs) 
such as tamoxifen or selective ER down-regulators (Howell et al, 2001) such 
as fulvestrant.  
 Although initially classified as competitive antagonists based on their 
ability to oppose estrogen action in the breast, it has become clear that 
SERMs, such as tamoxifen and raloxifene are pharmacologically more 
complex in that they manifest agonist or antagonist activity in a cell-selective 
manner. Both tamoxifen and raloxifene function as antagonists in the breast 
and as agonists in the bone. Active metabolite of tamoxifen, 4-
hydroxytamoxifen, is a mixed antagonist (i.e. that displays agonist or 
antagonist activity depending on the tissue) and ICI 182,780 (fulvestrant) is a 
pure antagonist. The partial antagonist tamoxifen binds to ligand binding 
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domain of ER to induce conformational change that prevents recruitment of 
co-activators necessary for activation of ERα specifically by recruiting co-
repressors to activation function 2 (AF-2) (Shiau et al, 1998). However, 
tamoxifen does not inhibit ligand independent AF-1. Hence, ER can still be 
stimulated in a ligand-independent fashion via cross-talk with other signaling 
pathways (Journé et al, 2008), making tamoxifen a partial antagonist. The use 
of tamoxifen is associated with 41% decrease in breast cancer recurrence and 
34% decrease in breast cancer mortality in postmenopausal women (Howell et 
al, 2005). Epidemiological studies on the other hand, have shown that 
tamoxifen use increases the occurrence of endometrial cancers in patients 
(Fotiou et al, 2000; Kloos et al, 2002; Rutqvist et al, 1995).  
 The search for anti-breast cancer drugs devoid of the estrogen-like 
uterotrophic activity of tamoxifen led to discovery of raloxifene (Jones et al, 
1979; Journé et al, 2008). Both tamoxifen and raloxifene causes ER 
intracellular accumulation without activating the receptor (Laïos et al, 2003). 
However, the pharmacokinetic properties (bioavailability and biological half-
life) of raloxifene proved to be less favorable than tamoxifen. Hence, the 
development of raloxifene as anti-estrogen for breast cancer therapy was 
discontinued in the late 1980s (Budzar et al, 1988).  
 Pure estrogen antagonist (fulvestrant) results in a rapid depletion of 
intracellular ER through proteasomal degradation (Journé et al, 2004; Laïos et 
al, 2005). Fulvestrant compete with estrogen for binding to ER. Its binding 
does not induce receptor dimerization (Chen et al, 1999) nor does it allow 
recruitment of co-regulators (Pike et al, 2001). As a consequence, fulvestrant 
is capable of blocking both AF-1 and AF-2 functions.  
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 Other drugs like aromatase inhibitors prevent ovarian and peripheral 
estrogen production from androgen by inhibiting the aromatization step. In 
general, there are two types of aromatase inhibitors (Type I and II). Type I 
inhibitors (formestane and exemestane) binds active site of aromatase, 
irreversibily or tightly, leading to inactivation of the enzyme. Type II 
inhibitors (anastrozole and letrozole) produce reversible aromatase inhibition 
(Journé et al, 2008). However, the use of these inhibitors leads to bone loss 
rate of about 2% per year, at least in the first 2-3 years of therapy, and 
increased fracture rate (Body et al, 2007).  
   
1.4.2 Selective estrogen receptor modulators (SERMs)  
 
Selective estrogen receptor modulators (SERMs) are a class of 
compounds that interact with intracellular ERs in target organs as estrogen 
agonists and antagonists, depending on the tissue type (Cho et al, 2001). These 
are chemically diverse molecules that lack the steroid structure of estrogens, 
but possess a tertiary structure that allows them to bind to ERα and /or ERβ. In 
the past, these compounds are known as estrogen agonists or antagonists, but 
recently, they have been reconsidered as selective estrogen receptor 
modulator.  
The agonistic and antagonistic activity of SERMs on estrogen target 
tissues can be explained through three mechanisms. Firstly, differential 
expression of ERα and ERβ, depending on the tissue type. Secondly, the 
differential conformation of ER upon ligand binding and thirdly, the 
differential expression and binding of ER co-regulators. Some examples of 
SERMs are tamoxifen (Nolvadex) and raloxifene (Evista). 
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Tamoxifen is an antiestrogen that prevented mammary cancer growth 
(Jordan, 1976; Lippman et al, 1975), but it is also estrogenic because it 
maintains bone density in ovariectomized rats (Jordan et al, 1987; Turner et al, 
1987; 1988). The concept of target tissue-specific effects of tamoxifen was 
strengthened by the discovery that tamoxifen prevented estrogen-stimulated 
breast cancer growth, but at the same time exhibited estrogenic activity 
through increase of uterine weight and stimulation of endometrial carcinoma 
(Gottardis et al, 1988; Jordan et al, 1987). This leads to the conclusion of 
tissue-specific action of tamoxifen and hence, it is termed as selective estrogen 
receptor modulator.   
Raloxifene was initially developed for breast cancer treatment but 
failed. It was reinvented as a drug for treatment of osteoporosis with lower 
incidence of breast cancer (Cummings et al, 1999). It maintained bone density 
in the rats, lowered circulating cholesterol and possessed low estrogenic 
activity in rodent uterus (Black et al, 1994).   
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1.5 Aryl hydrocarbon receptor 
1.5.1 Structure and function of AhR 
The aryl hydrocarbon (AhR), along with its nuclear binding partner 
AhR nuclear translocator (ARNT), is a ligand-activated transcription factor of 
the basic helix-loop-helix Per-Arnt-Sim (PAS) family of transcriptional 
regulators (Denison et al, 2003). These proteins are characterized by two 
conserved domains, the N-terminal basic helix-loop-helix domain and the PAS 
domain. The functional effect of AhR activation has been elucidated using 
ligands of toxicological concern, such as the polycyclic aromatic hydrocarbon 
benzo[α]pyrene, and a variety of halogenated aromatic hydrocarbons, known 
as environmental toxins. Of the latter group of chemicals, 2,3,7,8-
tetrachlorodibenzo-p-dioxin (TCDD) is the most potent AhR agonist, because 
of its high binding affinity and resistance to metabolism (Poland et al, 1976).  
 
1.5.2 AhR signal transduction pathway 
The unliganded AhR is sequestered in the cytosol by interacting with 
the Hsp90/XAP2 (also called as the ARA9 or AIP) chaperon complex 
(Hankinson, 1995; Poellinger, 2000). Ligand binding to the PAS-B domain of 
AhR is thought to induce conformational changes and subsequent 
translocation of the AhR complex to the nucleus (Hankinson, 1995; Poellinger, 
2000). AhR then dimerizes with the ARNT in the nucleus after dissociating 
from the chaperon complex, to recognize the xenobiotic-responsive element 
(XRE) which is also known as AhR-responsive element (AHRE) or Dioxin 
response element (DRE). Then AhR recruits co-activators such as histone 
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acetyltransferase p300/CBP, chromatin remodeling factor Brg1, and the 
mediator (DRIP/TRAP) complex to activate transcription (Hankinson, 1995; 
Poellinger, 2000). The AhR/ARNT heterodimer induces the expression of 
target genes such as CYP1A1, CYP1A2, and glutathione-S-transferase (Bock, 
1994). 
AhR is subjected to negative regulation after ligand induced activation 
and nuclear export (Ikuta et al, 2000). The receptor is subjected to degradation 
via 26S proteasome pathway (Ma et al, 2000). The activity of AhR-ARNT 
complex is also attenuated by the upregulation of a transcriptional repressor 
known as the aryl hydrocarbon receptor repressor (AhRR) (Hoffman et al, 
1991). AhRR is a basic helix loop helix-Per-Arnt-Sim (bHLH-PAS) protein 
with high sequence similarity to the AhR. AhRR binds ARNT and represses 
the interaction between ARNT and AhR complex with the dioxin responsive 
elements (DREs) (Mimura et al, 1999). This attenuation of the AhR by means 
of a negative feedback loop and receptor degradation may serve to protect the 
organism from the consequences of transcriptional hyper stimulation by potent 
agonists and also provide precise temporal control of the AhR pathway 
(Nguyen et al, 2008).  




Figure 1.2 Ligand activated signal transduction of AhR. (a) Ligand diffuses 
into the cell and is bound by the cytosolic AhR complex. (b) Ligand bound 
receptor complex translocates into the nucleus. (c) AhR dimerizes with ARNT, 
and together with co-regulator, it binds to DREs (d) leading to transcriptional 
activation of target genes. (e) AhR is exported to the cytosol and degraded. (f) 
The dimer of AhRR and ARNT down regulates the transcriptional activity of 
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1.5.3 Cross-talk of AhR with ERs 
Direct association of AhR with ERs has been independently reported. 
Ligand-activated AhR/ARNT associates with ERα and ERβ through the N-
terminal A/B region within ERs (Matthews et al, 2005; Ohtake et al, 2007; 
Ohtake et al, 2003; Wormke et al, 2003). By means of this association, the 
liganded AhR potentiates the transactivation function of estradiol-unbound 
ERα, while repressing estradiol bound ERα-mediated transcription on the 
estrogen-responsive element (ERE) (Ohtake et al, 2003). The interaction of 
AhR/ER is induced by different AhR ligands, such as TCDD, 3-
methylchlolanthrene and β-napthtoflavone (βNF). Activation of AhR is 
thought to be sufficient for the interaction with ERα because constitutively 
active form of AhR modulates ERα function in the absence of AhR ligand 
(Ohtake et al, 2008). These results suggest that the cross-talk of AhR with ER 
is initiated primarily through stimulation of AhR.  
The association of AhR/ERα has been shown by several independent 
approaches, including in vitro (Klinge et al, 2000), in vivo, and biochemical 
methods (Ohtake et al, 2007). Moreover, AhR/ERα cross-talk in the 
transcriptional regulation of ERα-responsive genes is abolished in AhR-
deficient mice (Mimura et al, 2003), confirming the specificity of  the 
molecular pathway in vivo (Ohtake et al, 2003). Reciprocally, estradiol-bound 
ERα associates with AhR bound to XRE to either potentiate (Matthews et al, 
2005) or repress (Beischlag et al, 2005) AhR-mediated transcription. In 
conclusion, the AhR/ERα complex may be able to bind to either XRE or ERE 
through the attachment functions of AhR or ERα, respectively. Alternatively, 
different complex subtypes that contain AhR/ERα may control promoter 
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selectivity. Reflecting this functional cross-talk, ARNT also acts as a co-
regulator for both ERα and ERβ (Brunnberg et al, 2003).  
 
1.5.4 Ubiquitin ligase activity of AhR and degradation of ERα 
TCDD is reported to decrease the ERα protein level in the rat uterus 
(Wormke et al, 2003), suggesting that AhR may also be involved in the 
control of protein stability. Upon activation of AhR by binding of AhR ligands 
such as 3-methylchlolanthrene and βNF, as well as by expression of 
constitutively active AhR, protein levels of endogenous ERα proteins are 
ubiquitinated for proteasome-mediated degradation (Ohtake et al, 2007; 
Wormke et al, 2003). 3-methylchlolanthrene-enhanced degradation of ER is 
attenuated in the presence of a proteasome inhibitor, MG132, and 3-
methylchlolanthrene-enhanced poly-ubiquitination of ERα is consistently 
observed irrespective of estradiol binding. Recently, it is shown that AhR 
activates ubiquitin-proteasome system by serving as an E3 ubiquitin ligase for 
degradation of ERα (Ohtake et al, 2007). 




Figure 1.3 Different modes of the AhR signaling pathways. Molecular 
pathways for AhR mediated biological actions. AhR may exhibit its biological 
actions through different pathways. Typically, AhR binds to its target gene 
promoters and induces expression of these genes. In addition, cross-talk of 
AhR with other transcription factors, as well as the function of AhR as an E3 
ubiquitin ligase is considered important for AhR biology. [Figure taken from 
(Ohtake et al, 2009)]. 
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1.6 Phytoestrogens and breast cancer 
1.6.1 Classification of phytoestrogens  
Phytoestrogens are broad group of plant-derived compounds with 
estrogenic activity; they bind to estrogen receptors and initiate estrogen-
dependent transcription (Kuiper et al, 1998). In general, the main classes of 
phytoestrogens are isoflavones, stilbenes, coumestans, flavonone and lignans 
(Moon et al, 2006; Sirtori et al, 2005). Flavonone such as prenylnaringenin is 
found in hops (Possemiers et al, 2006) and resveratrol from the stilbene group 
is found in red wine (Baur et al, 2006). Isoflavones such as genistein, daidzein 
and glycitein are mostly found in soy beans. Lignans are found in a more 
diverse group of plants, ranging from oilseeds, legumes, fruits, vegetables, 
whole grain cereals and flaxseed (Nesbitt et al, 1999). Table 1.4 shows the 
classes of phytoestrogens.  
Table 1.4 Classes of phytoestrogens. [Figure taken from (Rice et al, 2006)]. 
Flavones Flavonones Isoflavones Coumestans Lignans Stilbenes 
Apigenin Prenylnaringenin Genistein Coumestrol Enterolactone Resveratrol 
Quercetin Flavonone Biochanin 
A 
 Enterodiol  
Chrysin   Daidzein       
 
 
1.6.2 Functional similarity of phytoestrogens and estrogens 
  Phytoestrogens are biologically active phenolic found in plants with 
structure similar to estradiol. Shared structures include a pair of hydroxyl 
groups and a phenolic ring, which is required for binding to estrogen ERα and 
ERβ. It is thought that the position of these hydroxyl groups are determining 
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factors in their ability to bind to ER and activation of transcription (Le Bail et 
al, 2000).  
 Phytoestrogens binding to ERs can induce or attenuate a response. The 
morphology of the ligand binding domain (LBD) of ER, particularly the 
position of helix 12 is different, depending on the type of ligand that binds to 
the receptor. Genistein binding to the ER changes the conformation of helix 12 
to a position that is similar when raloxifene binds to ER (Setchell et al, 1980).  
 
1.6.3 Phytoestrogens and risk of breast cancer 
 Estrogens have been implicated in the initiation and promotion stages 
of breast cancer, with lifetime exposure to estrogen being a major risk factor 
for breast cancer development (Yager et al, 2006). This cancer stimulatory 
effect of estrogen is via the ER-dependent pathway as well as production of 
genotoxic metabolites (Bhat et al, 2003; Cavalieri et al, 2006; Yager et al, 
2006). Phytoestrogens having similar structural similarity with estradiol 
promotes breast cancer growth via ER pathway.  
 Epidemiologic evidence suggests that Asian women have fewer 
postmenopausal symptoms and experience fewer breast cancer cases than 
Western women, probably due to their high intake of soybean products 
(Adlercreutz, 2002; Nichenametla et al, 2006; Usui, 2006). Asian women have 
a 3-fold lower breast cancer risk than women in United States, independent of 
body weight (Ursin et al, 1994). On top of that, Asian women have 40% lower 
estradiol concentration in the serum as compared to their Caucasian 
counterparts (Peeters et al, 2003). This leads to the conclusion that dietary 
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factors affect the risk of breast cancer between the populations (Adlercreutz, 
2002; Nichenametla et al, 2006).  
 Case-control studies have been conducted to explore the role of 
phytoestrogens in breast cancer risk. In general, there has been no conclusive 
result on the risk of phytoestrogen on breast cancer risk. Some case-control 
studies have indicated protective effect of soy (Dai et al, 2001; Ingram et al, 
1997; Lee et al, 1992; Murkies et al, 2000; Shu et al, 2001; Wu et al, 1996). 
However, findings have been inconsistent, with some results showing no 
relationship between phytoestrogen intake and breast cancer development 
(Horn-Ross et al, 2001; Yuan et al, 1995; Zheng et al, 1999). Case-control 
studies have generally found more evidence for a protective role in 
premenopausal women versus postmenopausal women. This leads to the 
hypothesis that the effect of phytoestrogens are dependent on the hormonal 
status of the women, with stimulatory effect in low estrogen environment but 
inhibitory effect in high estrogen environment (Adlercreutz, 2002; Ju et al, 
2006).  
 
1.6.4 Potential mechanism for stimulatory effect of phytoestrogens on breast 
cancer 
Phytoestrogens are weakly estrogenic, with more than 1/100 times less 
estrogenic activity per mole as compared to estradiol. The physiological 
concentration of phytoestrogen ranges from 100 – 1000 fold higher than peak 
levels of endogenous estradiol in premenopausal women (Goldin et al, 1986; 
Limer et al, 2004; Zava et al, 1997). It is reported that the estrogenic activity 
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of the phytoestrogen in vivo is difficult to ascertain due to the presence of 
endogenous hormone, affecting the mechanism of phytoestrogen (Cassidy et 
al, 2006; Messina et al, 2006). Another important issue is the dosage of 
phytoestrogen. This is because, it is found that the effect of genistein on breast 
cancer is dose dependent, with genistein stimulating breast cancer cell growth 
at doses < 10 µM but inhibiting the growth therafter (de Lemos, 2001; Hsieh 
et al, 1998; Wang et al, 1998). Nevertheless, 10 µmol/L of genistein of 
genistein in the plasma is not easily achievable (Magee et al, 2004).   
The cancer growth stimulatory effect of phytoestrogen may be 
explained by their ability to alter the number of proteins that control cell cycle, 
induce cell cycle arrest and apoptosis (Mense et al, 2008). Resveratrol caused 
cell accumulation in the S-phase and down-regulation of Bcl-2 in MCF-7 and 
MDA-MB-231 cells, leading to apoptosis (Pozo-Guisado et al, 2002; Pozo-
Guisado et al, 2005). Resveratrol increased the expression and activity of G1/S 
and G2/M cell cycle regulators and increased the protein levels for p21, p53 
and p27 (Pozo-Guisado et al, 2002). Genistein and quercetin has also been 
found to cause G2/M cell cycle arrest and apoptosis (Balabhadrapathruni et al, 
2000).   
 
1.6.5 Potential mechanism for inhibitory effect of phytoestrogen on breast cancer 
Phytoestrogens appear to have preferential binding to ERβ and have 
sometimes been classified as selective ER modulators (SERMS) (An et al, 
2001; Brzezinski et al, 1999; Messina et al, 2006). Phytoestrogen binding to 
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ERβ may lead to protective effect against breast cancer growth (Strom et al, 
2004). 
 On top of that, phytoestrogens may give rise to protective effect 
against cancer growth via inhibition of aromatase that converts 
androstenedione and testosterone to estradiol (Rice et al, 2006). Over 60% of 
the breast tumors express aromatase and this expression is higher in malignant 
breast tissue as compared to normal tissue (Chetrite et al, 2000; Lipton et al, 
1992). Hence, the ability of phytoestrogens to inhibit aromatase activity may 
protect against estrogen dependent tumors. Flavones and flavonones are strong 
inhibitors of aromatase (Jeong et al, 1999; Le Bail et al, 2000; Sanderson et al, 
2004; Whitehead et al, 2003). The IC50 of aromatase inhibition by 
phytoestrogens is > 100 times the IC50 for steroidal inhibitor, 4-
hydroxyandrostenedione (Sanderson et al, 2004). In general, isoflavones are 
weak inhibitors of aromatase (Lacey et al, 2005; Le Bail et al, 2000). 
Surprisingly, study by Almstrup et al. showed that formononectin, biochanin 
A and extract from red clover flowers inhibited aromatase activity at 
concentrations less than 1 µM (Almstrup et al, 2002).  
 Phytoestrogens could inhibit cancer growth via nonhormonal pathways. 
This could include inhibition or downregulation of protein responsible for 
growth signaling pathway such as protein tyrosine kinase (PTK)(Akiyama et 
al, 1987; Barnes et al, 2000; Limer et al, 2004). Genistein has been shown to 
inhibit cell proliferation and regulation of apoptosis via inhibition of PTK-
mediated autophosphorylation and activation of epidermal growth factor 
receptor.  
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 Several phytoestrogens are known to modify the CYP450 enzyme by 
either inducing or suppressing the transcription of CYP450 enzymes (Moon et 
al, 2006). The expression of two main estrogen metabolizing enzymes 
CYP1A1 and CYP1B1 is under the control of the aryl hydrocarbon receptor 
(AhR). Resveratrol, genistein and quercetin have been shown to decrease both 
xenobiotic-induced transcription and activity of CYP1A1 and CYP1B1 in 
numerous cell types (Berge et al, 2004; Chan et al, 2003; Chang et al, 2001; 
Ciolino et al, 1999; Han et al, 2006). Resveratrol is an AhR antagonist and 
may inhibit CYP1A1 and CYP1B1 expression either through suppression of 
AhR DNA-binding activity or blocking the induction of AhR-induced genes 
(Casper et al, 1999; Chen et al, 2004). Similarly, genistein and quercetin 
decreases CYP1A1 and CYP1B1 mRNA expression by inhibiting the 
activation of XRE by AhR (Chan et al, 2003; Ramadass et al, 2003).  
In concentration higher than micromolar range, some phytoestrogens 
inhibit enzymes such as protein kinase and tyrosine kinase. This could give 
rise to their antiproliferative effects (Whitten et al, 1992).    
 Another mechanism by which phytoestrogen may exert their anticancer 
actions might be reduction of mammary sensitivity to carcinogens. Resveratrol 
exposure has been shown to decrease proliferation in mammary terminal 
ductal structures, making it less susceptible to carcinogen-induced damages 
(Whitsett et al, 2006). Exposure to genistein during breast development 
resulted in decreased terminal ductal formation (Hilakivi-Clarke et al, 1999).   
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1.7 Herba Epimedii flavonoids and cancer cell proliferation 
Herbal Epimedii, Berberidaceae (Chinese name “yingyanghuo” or 
“horny goat weed”) is a traditional Chinese herb consisting of the dried aerial 
part of several species of Herba Epimedii, including E. sagittatum, E. 
koreanum Nakai, E. pubescens Maxim, E.wushanense T.S. Ying and E. 
bervicornum Maxim. Herba Epimedii is a woody evergreen perennial 
indigenous to shady mountain areas in temperate to subtropical Asia. Chinese 
taxonomists and geneticists have variably reported the presence of 20 to 50 
different species of Herba Epimedii (Sun et al, 2005). 
 
1.7.1 Traditional use of Herba Epimedii  
  The use of Herba Epimedii dates back to the ancient text, Shen Nong 
Ben Cao Jing (ca. 200 B.C.-100A.D.). The herb is listed in Pharmacopoeia of 
the Peoples Republic of China as having action to “reinforce the kidney yang, 
strengthen tendons and bones, relieve rheumatic conditions” and is prescribed 
for “impotence, seminal emission, weakness of the limbs, rheumatoid 
arthralgia with numbness, muscle contracture and climacteric hypertension”. 
In recent years, Herba Epimedii has been extensively used for coronary 
diseases, hypertension, hyperlipidemia, hepatitis B, immunomodulation, as 
well as to alleviate menopausal discomfort. 
  
1.7.2 Modern use of Herba Epimedii  
 In recent years, Herba Epimedii has been extensively used for coronary 
diseases, hypertension, hyperlipidemia, hepatitis B, immunomodulation, as 
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well as to alleviate menopausal discomfort (Yang, 1985). The herb is also 
thought to have anti-cancer and anti-aging properties.  
 
1.7.3 Chemical constituents of Herba Epimedii  
In general, there are more than 130 different Herba Epimedii-derived 
compounds, including flavones and flavonoid glycosides have been isolated 
from over 16 species of the Herba Epimedii (Yap, 2005). Among them are 
flavonoid glycosides (e.g., icariin, baohuoside I), flavones (e.g., icaritin) and 
the icariside series. The total flavonoid content of several Herba Epimedii 
species ranged from 6.43% to 12.17% based on UV-visible spectrophotometry 
analysis (Wu et al, 2003). Major flavonoids isolated from Herba Epimedii 








Table 1.5 Major and minor flavonoid in Herba Epimedii species. The relative 
abundance of the flavonoid in ethanolic extracts from 37 Herba Epimedii was 
determined using liquid chromatography tandem mass spectrometry. [Figure 









(g/100g of dried 
ethanol extracts) 
Epimedin A 1.88 + 0.33 Quercetin 0.013 + 0.003 
Epimedin B 1.91 + 1.0  Luteolin 0.0080 + 0.002 
Epimedin C 7.41 + 0.91 
Breviflavone 
B 0.0075 + 0.001 
Icariin  3.04 + 0.30 Apigenin 0.0062 + 0.0019 
Kaempferol 0.0035 + 0.0009 
  
 
1.7.4 Geographical distribution of Herba Epimedii in China 
The geographical distribution of Herba Epimedii in China is well-
spread over different provinces, with majority of the total Herba Epimedii 
species being found in central-southeastern China (Ying, 2002). E. koreanum 
is found mainly in the northeastern district, E. brevicornum in the 
northwestern and northern district and E.sagittatum in the eastern and southern 
district respectively. In Sichuan province, E. acuminatum and E. pubescens are 
the main species. E. acuminatum, E. leptorrhizum and E. wushanense are the 
main species found in Guizhou province (Guo et al, 2003). 
 
1.7.5 Epimedium flavonoid and cancer cell proliferation  
 Herba Epimedii derived compound, baohuoside I exhibited cytotoxic 
and cytostatic effects on 6 different cancer cell-lines through inhibition of 
DNA and RNA synthesis (Li et al, 1990). Recently, a study on icariside II 
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isolated from the roots of Epimedium koreanum Nakai showed that it induced 
apoptosis of PC-3 prostate cancer cells via initiation of inhibition of the 
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) followed by 
subsequent apoptosis mediated by mitochondrial dependent pathway (Lee et 
al, 2009). The same compound was also shown to inhibit hypoxia-inducible 
factor-1alpha in human osteosarcoma cells (Choi et al, 2008). 
 In vitro MTT assay using HepG2 illustrated that icariin inhibited 
cancer cell proliferation in a concentration dependent manner (Yang et al, 
2009). Icariin also inhibited the tumor growth in HepG2 bearing NMRI nu/nu 
mice (Yang et al, 2009). However, the anti-tumor property of icariin is 
challenged by Lin et al because their in vitro experiment showed that icariin 
did not inhibit HepG2 cell proliferation (Lin et al, 2004). Table 1.6 shows the 
summary of in vitro experiments studying the anti-cancer properties of Herba 
Epimedii extract or flavonoid. The effect of Herba Epimedii-derived 
compound, icaritin, on cancer cell is discussed in the following chapter 
(Chapter 1.8). 
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Table 1.6 Summary of Herba Epimedii extracts and flavonoid and its effects on cancer growth. 






MTT assay was applied to test the anti-
proliferative effects of icariin in vitro. HepG2 
bearing NMRI nu/nu mice were used to test the 
anticancer effects of icariin in vivo. 
Icariin Icariin inhibited the proliferation of HepG2 cells in a 
concentration dependent manner; icariin also inhibited 
the tumor growth in HepG2 bearing NMRI nu/nu 
mice. The tumor weight was inhibited by 55.6% and 
tumor volume was inhibited by 47.2%.
Icariin inhibited the 







PC-3 prostate cancer cells  Icariside II Induction of apoptosis through its anti-inflammatory 
effects in PC-3 prostate cancer cells. Icariside II 
suppressed both constitutive and arachidonic acid 
(AA)-induced cyclooxygenase-2 (COX-2) expression 
as well as reduced prostaglandin E2 (PGE2) levels in 
PC-3 cells.  
Icariside II initiates the 
inhibition of COX-2/PGE2 
pathway and induces 
apoptosis mainly via 
mitochondrial dependent 





Human osteosarcoma (HOS) Icariside II Icariside II attenuated the protein level of HIF-1alpha 
induced by hypoxia in human osteosarcoma (HOS) 
cells in a concentration-dependent manner through 
down-regulation of the levels of HIF-inducible genes 
involved in angiogenesis, metastasis, and glucose 
metabolism, such as vascular endothelial growth 
factor (VEGF), urokinase plasminogen activator 
receptor (uPAR), adrenomedullin (ADM), matrix 
metalloproteinase 2 (MMP2), aldolase A, and enolase 
1. 
Icariside II is a therapeutic 
candidate against various 
diseases that involve 




Hepatoma SK-Hep1 cells Epimedin C Epimedin C decreased expression of 
hyperphosphorylated retinoblastoma (Rb) protein, 
cyclin D1, c-Myc, c-Fos, CDK2 and CDK4. It also 
selectively decreased ERK1/2 phosphorylation. 
Among the downstream effectors of ERK examined, 
Epimedin C selectively decreased the expression of c-
Fos, but not c-Jun. 
Epimedin C inhibited tumor 
growth via inhibition of 




MTT assay on four human cancer cell lines: 
lung cancer cells (Lu1), colon cancer cells 
(Col2), oral epidermoid carcinomas (KB) and 




No significant cytotoxic effect on the cancer cell lines 
tested. 
The Epimedium koreanum 
extract showed no cytotoxic 
effects against any of the 
cancer cell lines with or 
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MCF-7 cells Breviflavone 
B  
Breviflavone B exerted biphasic stimulatory and 
inhibitory effects on breast cancer cell proliferation. 
Potential anti-breast cancer 




Four human liver cancer cell lines, HepG2, 
Hep3B, SK-Hep1 and PLC/PRF/5, and four 
leukaemia cell lines, namely K562, U937, 
P3H1 and Raji 
E. sagittatum 
and icariin 
E. sagittatum extract inhibited the proliferation of all 
cell lines (SK-Hep1, PLC/PRF/5, K562, U937, P3H1 
and Raji). Icariin (the major compound of E. 
sagittatum) showed no inhibition of either the 
hepatoma or leukaemia cell lines. 
The inhibition of the cell 
proliferation by Herba 
Epimedii might not be due to 
icariin.  
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1.8 Icaritin and cancer cell proliferation 
1.8.1 Icaritin and cancer cell proliferation 
Herba Epimedii is officially listed in China as an herb that prevents the growth 
of cancer and has been listed by the Chinese Academy of Medical Sciences as 
one of an elite group of herbs that slow down aging and promote longevity 
(Yap, 2005). Icaritin is a metabolite from icariin, a major flavonoid found in 
Herba Epimedii.   
In human prostate carcinoma PC-3 cell line, icaritin inhibits cancer cell 
growth via G1 cell cycle arrest (Huang et al, 2007). When treated with icaritin 
for 24 to 72 hours, PC-3 cell growth was strongly inhibited, accompanied with 
a mitochondrial transmembrane potential drop. Icaritin increases protein 
expressions of pRb, p27(Kip1) and p16(Ink4a), while decreases the 
phosphorylated pRb, Cyclin D1 and CDK4, reflecting its effect on G1 cell 
cycle arrest (Huang et al, 2007).  
Icaritin induces apoptosis in HepG2 heptacellular carcinoma cells at 
doses of 5 – 50 µM (He et al, 2010). The effect is irreversible in the presence 
of estrogen antagonist ICI 182, 780, but reversible in the presence of specific 
inhibitor for c-Jun N-terminal kinase (JNK). This leads to the conclusion that 
the mechanism of increased apoptosis in HepG2 cell by icaritin is independent 
of ER signaling pathway but dependent on the JNK signaling pathway (He et 
al, 2010).  
Despite its protective effects in prostate cancer cells and hepatcellular 
carcinoma, studies in MCF-7 breast cancer cells have shown that icaritin is a 
phytoestrogen. Icaritin increased MCF-7 cell proliferation, with 90% increase 
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in relative proliferative effect (RPE) as compared to maximal proliferation in 
the presence of 1 nmol estradiol (Ye et al, 2005). The proliferative effect can 
be completely antagonized by estrogen receptor antagonist, ICI 182, 780 
(Wang et al, 2004; Ye et al, 2005). On top of that, icaritin increased 
expression of ER regulated genes, progestogen receptor (Ye et al, 2005), 
progesterone receptor and pS2 mRNA (Wang et al, 2004). The effects of 
icaritin on breast cancer growth are summarized in Table 1.7.    
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Table 1.7 Summary of effect of icaritin on cancer growth. 
1.7A. In vitro 




HepG2 hepatocellular carcinoma cells  Icaritin Icaritin (at 5-50 µM) induced apoptosis of HepG2 
cells. Icaritin was capable of stimulating the c-Jun N-
terminal kinase 1 (JNK1). Icaritin-induced cell 
apoptosis was abolished by SP600125, a specific 
inhibitor for JNK.  
Icaritin caused apoptosis in 





Human prostate carcinoma PC-3 cells Icaritin Inhibtion of PC-3 cell growth, accompanied with a 
mitochondrial transmembrane potential drop, G1 
arrest and G2-M cell cycle arrest.  









ICT and DICT increased proliferation of MCF-7 
cells with relative proliferative effects of 90% and 
94% respectively. Cell proliferation induced by ICT 
and DICT was completely antagonized by ICI 182, 
780. ICT and DICT increased progestogen receptor 
(PR) mRNA at 48 hours after treatment. 
ICT and DICT possess 
estrogen-like activity. Icariin 








ICT and DICT, but not ICA, strongly stimulated cell 
proliferation. This was associated with increased 
number of MCF-7/BUS cells in S and G2/M phase. 
Action of ICT and DICT can be inhibited by the 
specific estrogen receptor antagonist ICI 182,780.  
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1.8.2 Bioavailability of icaritin 
Although flavonoids such as icaritin occur only in trace amounts in the 
aerial parts of some Herba Epimedii species, it can readily be formed by 
progressive hydrolysis of major Herba Epimedii derived flavonoid, icariin or 
epimedin A, B or C, in the intestine and oral cavity (Shen et al, 2007b). Serum 
and urine from rats administered with Herba Epimedii extract showed 
presence of high icaritin level, due to in vivo metabolism of major Herba 
Epimedii flavonoid, icariin (Liu et al, 2005; Wong et al, 2009).   
Icariin has glucose and rhamnose residues on 7-OH of ring A and 3-
OH positions of ring C respectively (Figure 1.4). Partial deglycosylation of 
icariin results in icariside I and icariside II, which can be further 
deglycosylated into icaritin.  
In rat administered 600 mg/kg Herba Epimedii extract, the Cmax of 
icaritin and desmethylicaritin reached ~ 2 and ~ 0.25 µM respectively (Wong 
et al, 2009). In the same study, the author showed that the concentration-time 
profile of icaritin in rat serum after treatment with glucuronidase/sulphatase 
was the highest (Table 1.8).     
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Figure 1.2 Structures of icariin and its derivatives. Rha, rhamnose; Glu, 
glucose [Figure taken from (Wong et al, 2009)]. 




Table 1.8 Concentration-time profiles of Herba Epimedii prenylflavonoids. 
Rats were administered the indicated interventions. Concentrations of 
prenylflavonoids were determined by LC-MS/MS. Sera were examined before 
(A) and after (B) treatment with glucuronidase/sulphatase. [Figure adapted 
from (Wong et al, 2009)].   
(A)   Concentration nM h-1 


















11.6 538 198 41.5 37.3 
(B) Concentration nM h-1 
















734 33.96 × 103 7.69 × 103 
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1.9 Combinatorial effects of estradiol and phytoestrogen on 
cancer cell risk 
 Recently, there has been increasing interest to study the effect of 
phytoestrogen on cancer growth in the presence of estradiol. Phytoestrogens 
are plant-derived compounds that possess estrogenic activity. The most 
popular phytoestrogen currently being investigated in this light is the soy 
derived compound, genistein. Genistein is found in soy products such as tofu 
and soya bean drink, which is popular in Asian population. Genistein is a 
phytoestrogen, with stimulatory effect on MCF-7 breast cancer cells at doses 
less than 1 µM but decreases the proliferation at higher doses (Hsieh et al, 
1998; Wang et al, 1998). 
In general, research has shown that combination of phytoestrogen and 
estradiol showed mixed result with respect to cancer stimulatory and 
inhibitory effect. In ovariectomized Wistar rats, estradiol and genistein 
combination stimulated MCF-7 cell growth more than 30% compared to 
estradiol or genistein treatment alone (Ju et al, 2006). Measurement of the 
uterine weight also showed 57% and 11% increase in size compared to 
treatment with genistein and estradiol alone respectively (Ju et al, 2006). 
MCF-7 cells treated with estradiol and phytoestrogen (genistein, daidzein and 
coumestrol) combination showed reduced rate of apoptosis, measured using 
flow cytometry (Schmidt et al, 2005). The above results illustrated the pro-
proliferative effect of phytoestrogen and estradiol combination. 
However, there are also studies that showed inhibitory effect of 
phytoestrogens on estrogen stimulated cancer growth. Imhof et al. performed 
an ex vivo study by treating MCF-7 cells with sera from postmenopausal 
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women supplemented with Alsifemin (containing soy extract and standardized 
isfolavones) and/or estrofem FTLB (a HRT drug). It is found that at 
unphysiologically low estrogen level (10 pM), isoflavone caused minor 
proliferation enhancing effect. However, when the concentration of estradiol 
was > 20 pM, co-treatment with isoflavones caused significant anti-
proliferative effect in MCF-7 cells (Imhof et al, 2008).  Data from 
ovariectomized adult female cynomolgus monkeys also confirmed the 
estrogen level dependent effect of phytoestrogen treatment. In the study, soy 
isoflavones (genistein, daidzein, glycitein) resulted in lower serum estrone and 
estradiol level, lower estradiol-induced lobular Ki-67 expression (a marker for 
breast proliferation) and decreased uterine area only when the animal was 
given high estrogen doses (0.5 mg/day). This phenomenon was absent when 
the animals are given low estrogen doses of 0.09 mg/day (Wood et al, 2006).    
In ER sensitive LNCaP prostate cancer cells, genistein increased cell 
proliferation at low doses (5 µM) but decreased cell proliferation at higher 
doses (> 10 µM). However, genistein is able to decrease the effects of 
estradiol in promoting PC-3 cancer cell growth. Genistein also abrogated 
estradiol stimulation of prostate-specific antigen, a tumor marker for prostate 
cancer (Smith et al, 2008). The author hypothesized that genistein mediated 
inhibition of cancer growth could be due to the increased expression of 
CYP1A1 and COMT and 2-hydroxylation (Bradlow et al, 1999; Brueggemeier 
et al, 2001; Xu et al, 2000) leading to increase in 2-OHE2 (Smith et al, 2008) 
with weak estrogenic activity and decrease in 16α-OHE1, which has prolonged 
estrogenic activity (Swaneck et al, 1988; Telang et al, 1992).  The effects of 
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estradiol and phytoestrogen combination on cancer cell growth are shown in 
Table 1.9.  
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Table 1.9 Summary of effects of phytoestrogen and estradiol combination on cancer growth. 
1.9A. In vitro 
Source Assay Test substance Response Conclusions 
(Imhof et 
al, 2008) 
Effects of soy isoflavones on MCF-7 cells were 
investigated in the presence and absence of 
estrogen, directly and in a metabolized form by 
testing sera of postmenopausal women 






Only at unphysiologically low estrogen levels (10 pM) 
isoflavones led to minor proliferation-enhancing effects. In 
contrast, at estradiol levels of > 20 pM, isoflavones both 
tested directly and indirectly (metabolized) revealed 
significant anti-proliferative effects. 
Protective effect










DIM alone increased LNCaP growth, but when combined 
with E2, it decreased E2-induced proliferation. Genistein 
increased proliferation at low concentrations and decreased 
proliferation at higher concentrations. In combination with 
E2, 5 μmol/L genistein increased E2 stimulated LNCaP cell 
proliferation. At doses > 10 µM, GEN decreased E2-
stimulated LNCaP growth. GEN and DIM increased 2-
hydroxyestrogen (with weak estrogenic activity) and 
decreased 16a-hydroxyestrone (with prolonged estrogenic 
activity). 
DIM and > 10 µM of GEN 





MCF-7 cells were treated with compounds, alone or 









Phytoestrogen stimulated cell proliferation and inhibited 
apoptosis. Co-treatment of the phytoestrogen with estradiol 
did not affect cell proliferation, but reduced apoptosis. 
Stimulatory effect of estradiol 
and phytoestrogen on MCF-7 
cell growth is not result of 
stimulation of proliferation but is 
due to inhibition of apoptosis. 

















240 mg/day isoflavone dose resulted in significantly 
lower breast proliferation and uterine size in the 
high-estrogen (0.5 mg/day) environment. All 
< 0.05 The anti-estrogenic effect of isoflavone is dependent on 
estradiol level. 










isoflavone doses resulted in lower serum estrone and 
estradiol concentrations in the high-estrogen 
environment. In contrast, isoflavone treatment had 
no significant estrogen agonist effect and minimal 












Tumor size with estradiol treatment is 67.4 mm2, 
genistein alone, 32.1 mm2; genistein + estradiol, 
106.8 mm2. The average uterine weight is 
significantly larger with genistein plus estradiol 
treatment compared to compound alone. 
< 0.05 Genistein in the presence of low levels of circulating 
estradiol act in additive manner to stimulate breast cancer 
cell growth. 
 




Phytoestrogens are essential components of the human diet. 
Phytoestrogen like icaritin have been reported to have beneficial effects on 
bone and neuronal health (Wang et al, 2007b; Zhang et al, 2009). However, 
their utility is limited by the concern that being estrogenic, ingestion of 
phytoestrogens may stimulate the growth of estrogen-responsive breast cancer 
cells. Besides exogenous estrogens, endogenously produced estrogens such as 
estradiol, contribute to the estrogenic milieu driving the growth of breast 
cancer cells. Because these studies were conducted in the absence of 
endogenous hormone, the physiological releveance of these findings is not 
clear. To fully understand the estrogenic drivers for breast cancer cells, 
combinatorial effects of both endogenous and exogenous estrogens need to be 
examined together. 
Our aim is to study the potential of icaritin to be co-administered with 
hormone replacement therapy to modulate the increase in breast cancer risk.  
In this study, combinatorial effect of icaritin and estradiol would be 
systematically characterized by examining their binding to ERα, ability to 
induce endogenous ER-regulated gene expression and ERα promoter activity. 
We would also use the bioinformatics approach to identify genes that may be 
differentially regulated by icaritin. Such novel icaritin-regulated genes will be 
studied systematically and characterized by molecular biology techniques. 
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CHAPTER 2 MATERIALS and METHODS 
2.1 Materials 
2.1.1 Cell culture media, supplements, trypsin and antibiotics 
Description Source 
Cell culture media 
 Eagle’s minimum essential 
medium (EMEM; phenol red 
free) 
 Leibovitz Medium (L-15) 
Sigma-Aldrich, USA 
Supplements 
 Fetal bovine serum (FBS) 
 L-glutamine 
 Non-essential amino acids 
 Sodium pyruvate 
 Sodium bicarbonate 
 Bovine insulin 
      
 
     
GIBCO-BRL, Life Technologies, USA 
 
 
 Sigma-Aldrich, USA 
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2.1.2 Compounds and antibodies  
 
The compounds were dissolved in DMSO. 
 
Description Source 
Test compounds  






 Icaritin  
 [3H]-estradiol 




 Proteasome inhibitor, MG132 
 
    
           




Schwabe Pharmaceutical, Germany 






 Mouse anti ERα (F-10)   
 Mouse anti ERβ   
 Goat anti-mouse secondary 
antibody 
Santa Cruz Biotechnology, CA, USA 
Sigma-Aldrich, USA 
Dako, USA 
Dr. Steven Safe (Texas 
A&M University, USA).  
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2.1.3 Assay systems  








2.1.4 Equipments  











 Cyquant Cell Proliferation 
Assay Invitrogen, CA 
 Luciferase Assay System Promega, Madison, WI 





 Fluorescence microplate 
reader 
Tecan US, Research 
Triangle Park, NC 
 GloMaxTM 20/20 
Luminometer Promega, USA 
 iBlot® Dry Transfer System  Invitrogen, Carlsbad, CA 
 Illumina Sentrix HumanRef-8 
V2 BeadChip Arrays Illumina, Cambridge, UK 
 Illumina BeadArray Reader Illumina, Cambridge, UK 
 ND-1000 Spectrophotometer  
NanoDrop Technologies, 
USA 
 Nucleofector Kit V Lonza, Cologne, AG 
 Scintillation Counter  
1409, Wallac, Turku, 
Finland 
 StepOnePlus Real Time PCR 
System Applied Biosystem, USA 
 X-Ray Developer Carestream Health, USA 
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2.1.5 Probes for real-time PCR  








  All of the siRNAs were purchased from Qiagen, USA. 
 
Taqman Gene Expression Assay Mix  Catalog number  
 CYP1A1 Hs00153120_m1 
 AhR Hs00907314_m1 
 GREB1 Hs00536409_m1 
 18S rRNA 4319413E 
siRNA Catalog number 
 AhR SI02780148 
 Scrambled 1027280 
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2.2 Mammalian cell culture 
All of the cells were routinely propagated and cultured at 37 °C in a 
humidified, 5% CO2 atmosphere. Before experiment, cells were grown in 
dextran-coated charcoal treated Fetal Bovine Serum (FBS).  
 
2.2.1 Dextran-coated charcoal treated FBS preparation 
4C Norit A charcoal and dextran T-70 were added in a solution 
containing 0.25 M sucrose, 1.5 mM MgCl2, 10 mM Hepes. The final 
concentration of charcoal and dextran was 0.25% and 0.0025% respectively. 
The solution was incubated overnight at 4 °C. Equal volume of dextran-coated 
charcoal to the volume of serum which was to be charcoal stripped was 
aliquoted. The solution was centrifuged at 12,000 rpm for 15 minutes to pellet 
the dextran-coated charcoal. The supernatant was removed and replaced with 
same volume of serum. The tube was vortexed to thoroughly mix the charcoal 
with the serum. The serum with dextran-coated charcoal mixture was 
incubated for 12 hours at 4 °C. This was followed by a centrifugation at 
12,000 rpm for 15 minutes to pellet the dextran-coated charcoal. The serum 
was removed and filtered through 0.2 µM PES filter head (Nunc, Roskilde, 
Denmark). 
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2.2.2 MCF-7 cell line 
MCF-7 cells were obtained from American Type Culture Collection 
(Manassas, VA). The cells were routinely maintained in Eagle’s minimum 
essential medium (EMEM; Sigma-Aldrich, USA) supplemented with 10% 
complete FBS, 2 mM L-glutamine, 1 mM sodium pyruvate and 3.5 mM 
sodium bicarbonate. One week before experiment, the cells were grown in 
media with 10% dextran-coated charcoal treated fetal bovine serum (FBS). 
 
2.2.3 MDA-MB-231 cell line 
MDA-MB-231 cells were obtained from American Type Culture 
Collection (Manassas, VA). The cells were routinely maintained in Leibovitz 
Medium (L-15; Sigma-Aldrich, USA) with 10% FBS. One week before 
experiment, the cells were grown in media with 10% dextran-coated charcoal 
treated FBS. 
 
2.2.4 ERα stable cell line 
HeLa cells were obtained from American Type Culture Collection 
(Manassas, VA). The cells were stably transfected with four tandem copies of 
estrogen response element upstream of luciferase reporter gene (ERE4-Luc) 
(Wong et al, 2007). These cells are termed as ERα stable cell line. ERα stable 
cell line were maintained in EMEM supplemented with 10% complete FBS, 2 
mM L-glutamine, 1 mM sodium pyruvate, 3.5 mM sodium bicarbonate, 0.5 
mM G418 and 0.2 mM hygromycin. One day before experiment, the cells 
were grown in media with 10% dextran-coated charcoal treated FBS. 
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2.3 Human breast cancer cell proliferation assay 
The cells were grown in dextran-coated charcoal treated FBS for seven 
days prior to cell proliferation assays. Cells were seeded into 96-well 
microtitre plates at initial density of 4,000 cells per well. Cells were allowed to 
attach with overnight incubation. The media was decanted and 100 µL of fresh 
media containing test compounds was added. Final DMSO concentration in 
culture media did not exceed 0.5% (v/v). The cells were incubated with media 
containing compounds for 6 days with media renewal every two days. All the 
experiments were done in four replicates. The cell proliferation was 
determined using Cyquant™ Cell Proliferation Assay (Invitrogen, CA). The 
media was removed by gently inverting the microplates onto paper towels. 
The microplates were stored at -70 °C for 5 hours. After that, the cells were 
thawed at room temperature for 10 minutes, followed by addition of 200 μL of 
the CyQUANT® GR dye/cell-lysis buffer to each sample well. The plates 
were incubated for 5 minutes at room temperature, protected from light. The 
sample fluorescence was measured using a fluorescence microplate reader 
with filters of 480 nm for excitation and 520 nm for emission (Tecan, USA). 
Cell growth was expressed as fold-increase in optical absorbance compared to 
the control (DMSO treated) cells. 
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2.4 Plasmid DNA purification and nucleofection 
2.4.1 Plasmid DNA purification 
The XREX2-TATA-LUC and FLAG-AhR plasmids were kindly 
provided by Dr Shigeaki Kato from Institute of Molecular and Cellular 
Biosciences, The University of Tokyo, Japan (Ohtake et al, 2003).  
 1 μL of plasmid DNA was added to 100 μl suspension of DH5α super-
competent cells. The suspension was incubated on ice for 10 minutes. This 
was followed by heat shock in water bath at 42 °C for 90 seconds and 
incubation on ice for 2 minutes. 200 μl of SOC medium was added. The 
suspension was incubated for 45 minutes at 37 °C with vigorous shaking (230 
cycles/minute). The suspension was spread onto LB agar plate containing 
ampicillin. The plates were incubated overnight at 37 °C.   
A single transformed colony was picked from the LB agar plate and 
inoculated into 2 mL of LB medium containing 100 μg/mL ampicillin in a 10 
mL culture tube to get the starter culture. The loosely capped culture tube was 
incubated for 8 hours at 37 °C with vigorous shaking at 230 cycles/minute. 
500 µL of the starter culture was then added to 500 mL LB medium 
containing ampicillin (100 µg/mL). The flask was incubated overnight at 37 
°C with vigorous shaking at 230 cycles/minute. The next day, the bacteria 
culture was centrifuged to remove the LB. Large-scale plasmid DNA 
purification was performed according to the manufacturer’s instructions using 
QIAprep Spin Maxiprep Kit (Qiagen, USA).  
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2.4.2 Plasmid DNA nucleofection 
The MCF-7 cells were transfected using Amaxa® Cell Line 
Nucleofector® Kit V (Lonza, Cologne, AG) according to manufacturer’s 
specification. 2 × 106 cells were mixed with 1 µg plasmid DNA and 100 µL 
cell line nucleofector® Solution V. Program-020 was used for the 
nucleofection. After nucleofection, the cells were transferred to either 24-well 
plates or 96-well plates. The cells were seeded at density of 1 × 105 cells/well 
and 1 × 104 cells/well in 24 and 96 well plate respectively.  
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2.5 Reporter gene assay  
2.5.1 ER responsive reporter assay 
ERα stable cell line (refer section 2.2.4) were plated in 96 well plates 
at a density of 1 × l04 cells per well. The next day, cells were supplemented 
with fresh media containing compounds After 24 hours incubation; the cells 
were lysed with Passive Lysis Buffer (Promega, USA). The luminescence was 
measured with Luciferase Assay System in a GloMax™ 20/20 Luminometer 
(Promega, USA) following the manufacturer’s instuction. Transcriptional 
activity was calculated with respect to the transcriptional response towards 10 
nM estradiol (100%). 
 
2.5.2 AhR responsive reporter assay 
The MCF-7 cells were nucleofected with pXRE-Luc as detailed in 
section 2.4.2. The cells were seeded at density of 1 × 105 cells/well in 24 well 
plate.  
After overnight incubation, cells were incubated with media containing 
compounds for 24 hours. The cells were lysed using Passive Lysis Buffer 
(Promega, Madison, USA) and the luminescence was measured with Dual 
Luciferase Assay System (Promega, Madison, USA) in a GloMaxTM 20/20 
Luminometer (Promega, USA) following the manufacturer’s instruction. 
Transcriptional activity was normalized against vehicle (DMSO treated cells) 
readings.  
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2.6 Real-time PCR experiment 
2.6.1 Total RNA extraction 
MCF-7 cells grown for a week in dextran-coated charcoal treated 
EMEM were plated in six-well plates at density of 1 × 106 cells/well. The cells 
were incubated with compounds for 6 hours. This is followed by washing with 
phosphate buffered saline (PBS) and total RNA isolation using RNeasy Mini 
Kit (Qiagen, Valencia, CA), according to manufacturer’s instruction. RNA 
was eluted with 40 μL of RNAse free water. RNA quality control and 
quantification were determined using the ND-1000 Spectrophotometer 
(NanoDrop Technologies, USA). Only RNA with a quality ratio A260/A280 
between 1.9 and 2.1 and no evidence of peak degradation (18s/28s) was used. 
RNA samples were then aliquoted and stored at -80 °C until use. 
 
2.6.2 cDNA synthesis 
First-strand cDNA synthesis was generated from total RNA using 
SuperScript™III Reverse Transcriptase (Invitrogen, USA) according to 
manufacturer’s instruction.  
500 ng total RNA, 50 ng random primers, 4 µL 10 nM dNTP and 
water to make up 13 µl was prepared. The mixture was subjected to cycling 
condition of 65 °C for 5 minutes, then 4 °C for 1 minute. This is followed by 
addition of 4 µL 5 × first strand buffer, 1 µL 0.1M DTT, 1 µl RNasin and 1 
µL SuperScript III. The mixture was subjected to cycling condition of 25 °C 
for 5 minutes, 50 °C for 60 minutes and then 70 °C for 15 minutes. 
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2.6.3 Real-time PCR 
The cDNA was diluted 100 × before use. The real-time PCR was 
performed in StepOnePlus Real-Time PCR System (Applied Biosystem, USA). 
All the experiments were performed in triplicates. Non-template controls 
(NTC) were included each time for quality control. Data were normalized 
against time-matched DMSO and ribosomal 18s levels.  
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2.7 Western blotting  
2.7.1 Cellular protein extraction 
MCF-7 cells were plated at density of 0.2 × 106 per well in 24 well 
plate. After overnight, the cells were incubated with test compounds for 24 
hours. The cells were added with 80 µL M-PER Mammalian Protein 
Extraction Reagent (Thermo Scientific, Waltham, MA) mixed with mini 
EDTA protease inhibitor cocktail (Roche, USA). Protein concentration was 
determined using Bio-Rad Bradford protein assay (Bio-Rad Laboratories, 
Hercules, CA). Serial dilution of bovine serum albumin (BSA) standard (Bio-
Rad, USA) was prepared each time to obtain the protein standard curve.  
 
2.7.2 SDS-polyacrylamide gel electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was performed 
according to standard protocols using the Mini PROTEAN 3 electrophoresis 
cell (Bio-Rad, USA). Protein samples in SDS-loading buffer (final 
concentration - 2 mM dithiothreitol, 40 mM Tris-HCl (pH 6.8), 2% SDS, 0.1% 
bromophenol blue, 4% glycerol and 2.5% β mercaptoethanol) was heated at 95 
°C for 5 minutes before loading onto a 10% SDS-PAGE gel. Electrophoresis 
was carried out in 1 × running buffer (25 mM Tris, 192 mM glycine, 0.1% 
SDS) at 100 V for 3 hours. 
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2.7.3 Western blot detection and analysis 
After electrophoresis, the protein was transferred to the nitrocellulose 
membrane using iBlot® Dry Transfer System (Invitrogen, Carlsbad, CA) 
using program P3, 7 minutes. Then, the membrane was blocked at room 
temperature for 60 minutes in 5% skimmed milk in PBS with 0.1% Tween 20 
(PBST). This is followed by overnight incubation at 4 °C with anti ERα 
antibody (F-10, Santa Cruz Biotechnology, CA, USA) (1:500 dilution) or anti-
β-actin antibody (Sigma-Aldrich, USA) (1:10000 dilution). After 4 times (10 
minutes each) washing with PBST, the membrane is incubated with anti-
mouse secondary antibody conjugated to horseradish peroxidase (Dako, USA) 
(1:10000 dilution). The membrane is washed for 4 times, 10 minutes each, 
using PBST. SuperSignal West Femto Maximum Sensitivity Substrate 
(Thermo Scientific, Rockford, USA) was added and the protein signal was 
detected using X-Ray Developer (Carestream Health, USA). The intensity of 
the bands was quantified by ImageJ (NIH, USA). The normalized band 
intensity is expressed as fold ERα band intensity over loading control, β-
actin’s band intensity. 
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2.8 Competitive ligand binding assay 
2.8.1 ERα competitive ligand binding assay  
ERα stable cell line (refer section 2.2.4) was plated in 24 well plates at 
density of 1 × 105 cells/well. After overnight incubation, the media was 
replaced with fresh EMEM containing 6% FBS, 0.2nM [3H]-estradiol and 
icaritin or estradiol. After 19 hours incubation, media was discarded and the 
cells were rinsed with 400 µL ice-cold PBS for three times. 150 µL of M-PER 
Mammalian Protein Extraction Reagent (Thermo Scientific, Waltham, MA) 
was added, followed by 5 minutes of gentle shaking. 130 µL of total cell 
lysate was mixed with 2.5 mL of Liquid Scintillating Cocktail and 3H bound 
radioactivity was counted for 1 minute per vial using scintillation counter. 5 
µL of the cell lysates were used for protein quantification using Bio-Rad 
Bradford protein assay (Bio-Rad Laboratories, Hercules, CA) with serially 
diluted BSA as standard. 
Non specific binding was assessed by exposing cells to 250-fold excess 
unlabelled estradiol. Specific bound icaritin was expressed as dpm/mg protein. 
Each data points represented the mean of three replicates. 
 
2.8.2 AhR competitive ligand binding assay  
This experiment was performed by Dr Denison’s lab, USA. Male 
C57BL/6 (20 g) were purchased from Charles River Laboratories (Wilmington, 
MA) and maintained in a 12 hour light : 12 hour dark cycle with free access to 
food and water.  Hepatic cytosol was prepared in HEDG buffer (25 mM Hepes, 
pH 7.5, 1 mM EDTA, 1 mM DTT, 10% (v/v) glycerol) as previously 
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described (Denison 2002). Cytosolic protein concentrations were determined 
by dye binding (Bradford, 1976) and the samples were stored at -80 °C until 
use.  Aliquots of mouse hepatic cytosol (2 mg/ml) were incubated with 2 nM 
[3H]-TCDD in the presence of DMSO (1%), TCDF (200 nM), or increasing 
concentrations of icaritin for 2 hours in a room temperature water bath.  [3H]-
TCDD binding in aliquots of the incubation (200 mL) was determined by HAP 
binding as previously described (Denison, 2002).  The total amount of [3H]-
TCDD specific binding was obtained by subtracting the non-specific binding 
from the total binding.   
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2.9 AhR knockdown 
MCF-7 cells were transfected with 300 nM small interfering RNA 
against AhR (siAhR; Qiagen, USA) or negative control scrambled siRNA 
(siScrambled; Qiagen, USA). Transfection was performed using Amaxa® Cell 
Line Nucleofector® Kit V (Lonza, Cologne, AG) according to the 
manufacturer’s instructions as per detailed in Section 2.4.2. The efficiency of 
knockdown was verified by real-time PCR in a StepOnePlus Real Time PCR 
System (Applied Biosystem, USA). 
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2.10 Global gene expression profiling  
Total RNA was extracted as per detailed in Section 2.6.1. Total RNA 
was amplified to yield biotinylated cDNA and then purified using the 
Illumina® TotalPrep™ RNA amplification kit (Ambion) according to the 
manufacturer's instructions. 550 ng of total RNA was reverse-transcribed to 
cDNA using a T7 oligo(dT) primer. Second strand cDNA was synthesized and 
transcribed to cRNA and labeled with biotin-NTP. After purification, the 
cRNA was quantified using the ND-1000 spectrophotometer.   
Gene expression analysis was executed using Illumina Sentrix 
HumanRef-8 V2 BeadChip Arrays (Illumina, Cambridge, UK) allowing the 
analysis of ~23,000 transcripts. Firstly, 750 ng of amplified biotinylated 
cRNA were hybridized onto the Illumina Sentrix BeadChip in a hybridization 
cartridge under humidified conditions for 20 hours at 58 °C in a hybridization 
oven. The chips were then washed, stained for 10 minutes with 1 μg/mL 
streptavidin-conjugated Cy3 (Amersham Biosciences), and finally dried by 
centrifugation according to the manufacturer’s protocol. Fluorescence 
detection was carried out by confocal laser scanning with the Illumina 
BeadArray Reader (Illumina, Cambridge, UK) at 532 nm and 0.8 μm 
resolution.  
Illumina BeadStudio Software (Illumina, Cambridge, UK) was used 
for condensing the data and ensuring high array quality based on different 
control bead parameters. Data were extracted and normalized using the rank 
invariant method available in the BeadStudio software.  
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Genesifter software (Geospiza) was used to identify differential gene 
expression due to ER-dependent regulation, microarray data from triplicate 
experiments were subjected to Analysis of Variance (ANOVA) using the 
criteria where a regulated gene is defined to be one that was activated by at 
least 2-fold or greater and statistically different from the control cells treated 
with DMSO where the adjusted p-value using the Benjamini and Hochberg 
procedure (BH-adjusted P-value) is less than 0.0001 (Hochberg et al, 1990).  
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2.11 Statistical analysis 
Values are expressed as mean + SEM. The significance of the 
difference between the respective controls for each experimental test 
conditions was assayed using Student’s t-test for each paired experiment. A P 
value of < 0.05 was regarded as indicating a significant difference.  
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CHAPTER 3 RESULTS 
3.1 Icaritin as a phytoestrogen 
 The hallmark physiologic response to estrogenic stimuli is the 
proliferation of the cells in vivo. This can be mimicked in vitro by using 
established cell lines, such as MCF-7 cells which express endogenous estrogen 
receptor alpha (ERα) and are responsive to estrogens and anti-estrogens 
modulated cell proliferation. In general, there are three commonly used ERα 
positive cell lines, MCF-7, T47D and ZR75.1. However, MCF-7 is by far the 
most widely used cell line with 5774 citations in 2003 compared to 866 and 
590 citations for T47D and ZR75.1 respectively (Burdall et al, 2003). MCF-7 
cell proliferation assay is able to measure the physiological endpoint of 
estrogen actions through measurement of cell number at the end of the 
experiment. MDA-MB-231 (MDA), an ERα negative breast cancer cells was 
used to test the ERα specific activity of icaritin. As positive and negative 
control treatment, MCF-7 cells were incubated with either estradiol or 4-
hydroxytamoxifen respectively. We used 4-hydroxytamoxifen instead of 
tamoxifen as the negative control because 4-hydroxytamoxifen is an active 
metabolite of tamoxifen and is 100 times more potent in reducing the S- and 
G2-M phase leading to decreased cell number (Reddel et al, 1983). 




3.1.1 Icaritin induced a dose-dependent stimulatory/inhibitory effect on MCF-7 
proliferation  
MCF-7 cells were exposed to estradiol or icaritin and their effect on 
cell growth was measured. Estradiol alone dose-dependently induced MCF-7 
cell growth with Cmax at 10 pM (Figure 3.1A). In comparison, the ERα 
antagonist, 4-hydroxytamoxifen did not induce MCF-7 cell proliferation 
(Figure 3.1A).  
Similar to estradiol, icaritin alone dose dependently induced cell 
proliferation with EC50 of 0.8 µM and Cmax of 5 µM. Maximal proliferative 
effects of icaritin were similar to those observed with estradiol and genistein, 
and their relative potencies were in order icaritin < genistein < estradiol. 
However, cell growth in the presence of icaritin decreased when doses 
exceeded 10 µM (Figure 3.1A). The inhibitory effect was unlikely to be due to 
non-specific toxicity because the same doses of icaritin did not decrease MDA 
cell number (Figure 3.1B). The growth stimulatory effect of icaritin was 
specific for ERα because no cell growth was observed when ERα- MDA cells 
were treated with icaritin.  
Genistein was included as flavonoid control because MCF-7 cell 
growth with genistein treatment was well documented. Growth of MCF-7 cells 
treated with genistein also showed a dose-dependent stimulatory/inhibitory 
curve with maximal cell growth at 30 nM. At dose greater than 1 µM, 
genistein decreased MCF-7 cell proliferation (Figure 3.1A). This trend was 
consistent with previously published data (Hsieh et al, 1998; Wang et al, 
1998), where genistein stimulated MCF-7 proliferation at doses between 10 
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nM and 1 µM but inhibited MCF-7 proliferation at concentration thereafter. 
Thus, both icaritin and genistein caused a biphasic stimulatory/inhibitory 
MCF-7 cell proliferation, although icaritin was approximately 100 times 
weaker than genistein. 


























































Figure 3.1 Effect of icaritin on MCF-7 or MDA cell proliferation. (A) Breast 
cancer cells (MCF-7) or (B) MDA cells were  incubated with indicated doses 
of estradiol (E2), 4-hydroxytamoxifen (4-OHT), icaritin (ICT) or genistein 
(GEN). Cell proliferation was measured after 6 days using Cyquant™ Cell 
Proliferation Assay. All data points represented fold increase in proliferation 
relative to the untreated (DMSO) control (mean + S.E.M., n=4).  
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3.1.2 Icaritin bound directly to ERα  
We proceeded to perform a radioligand binding assay to test the direct 
binding of icaritin to ERα. The level of specific binding of icaritin to the ERα 
receptor was determined in the presence of competing radioactive [3H]-
estradiol. IC50, which was the concentration of icaritin which displaced 50% of 
the specific binding of the [3H]-estradiol was determined.  
Competitive binding assays indicated that icaritin was a bona-fide 
estrogenic ligand, with IC50 of 7.3 × 10-6 M (Figure 3.2). Specific [3H]-
estradiol binding was completely inhibited by 2.5 × 10-5 M of icaritin. IC50 of 
estradiol was approximately 700 times lower, 1.8 × 10-10 M. We can thus 
conclude that icaritin is an ERα agonist, albeit a weak one.  
 
 



































Figure 3.2 Competitive binding of icaritin to ERα. HeLa cells stably 
expressing ERα were exposed to 0.2 nM of [3H]-estradiol and increasing doses 
of unlabeled estradiol or icaritin for 19 hours at 37 °C. Unbound ligand was 
washed off and receptor bound [3H]-estradiol was measured using scintillation 
counter. Specific counts in dpm were obtained by subtracting non-specific 
binding from total counts and normalized against protein concentration. The 
readings were expressed as percentage [3H]-estradiol counts in the absence of 
competitor. n=3, data are mean + S.E.M. for triplicate readings from one 
representative experiment.  
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3.2 Combinatorial effect of estradiol and icaritin  
3.2.1 Estradiol/icaritin in combination exerted lower proliferative effect than 
estradiol alone 
Next, we examined the effects of icaritin in combination with estradiol. 
The was because there is endogenous production of estrogens in women. 
Thus, the summated effects of all estrogens in the body would be more 
relevant than individual compounds alone. We have chosen the dose of 100 
pM which mimicked the level in postmenopausal women with hormone 
replacement therapy (Yasui et al, 2005). MCF-7 cells were exposed to 
increasing doses of icaritin in the presence of 100 pM estradiol (Figure 3.3A).  
In contrast to the strong proliferative effects of estradiol or icaritin alone, the 
presence of icaritin at doses > EC50 suppressed estradiol-stimulated cell 
growth (Figure 3.3B) 
We tested if the modulator effect of 1 µM icaritin on estradiol 
stimulated MCF-7 cell proliferation was effective over different doses of 
estradiol. Figure 3.3B showed that when cells were exposed to a fixed dose of 
icaritin (1 µM), estradiol even at high doses were not able to induce maximal 
cell growth. Hence, icaritin modulated estradiol stimulated MCF-7 
proliferation. Maximal cell proliferation with the estradiol/icaritin combination 
was about a third lower than that observed with estradiol alone.  
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Figure 3.3 Effect of estradiol and icaritin combination on MCF-7 cell 
proliferation. MCF-7 cells were incubated with indicated doses of (A) icaritin 
with/without 100 pM estradiol or (B) estradiol with/without 1 µM icaritin. 
Proliferative effects of ligand alone or in combination of icaritin with estradiol 
were measured using Cyquant™ Cell Proliferation Assay. All data points 
represented fold increase in proliferation relative to the untreated (DMSO) 
control (mean + S.E.M., n=4) *, P < 0.05, comparing MCF-7 proliferation 
after icaritin or estradiol alone with estradiol/icaritin incubation. 
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3.2.2 Estradiol/icaritin in combination induced lower GREB1 gene expression 
compared to either ligand alone  
To further delineate the genomic effects of the icaritin/estradiol, we 
performed mRNA expression studies with GREB1, a gene that is critically 
involved in estrogen-induced growth of breast cancer cells (Grandien et al, 
1995; Rae et al, 2005), and asked whether growth effects were associated with 
changes in estrogen-regulated gene expression. GREB1 is one of the ERα-
responsive genes that are upregulated in the presence of ERα agonist. 
Suppression of GREB1 using siRNA blocked estrogen induced growth in 
MCF-7 cells (Rae et al, 2005). GREB1 is an early response gene, with a 
detectable increase in the mRNA level after 6 hours of treatment with estradiol 
(Ghosh et al, 2000).  
 Using quantitative real-time PCR, GREB1 mRNA was detectable after 
6 hours of treatment with estradiol (Figure 3.4B). A dose-dependent increase 
in GREB1 mRNA was observed with icaritin treatment (0.01 to 1 µM) (Figure 
3.4A), consistent with cell proliferative effects. As expected, the presence of 
4-hydroxytamoxifen reduced GREB1 mRNA to basal levels. Remarkably, the 
combination of estradiol/icaritin resulted in a 65% and 52% reduction in 
GREB1 mRNA expression compared to estradiol and icaritin respectively 
(Figure 3.4B). This suppressive effect was stronger than that observed for the 
4-hydroxytamoxifen/estradiol combination (Figure 3.4B). 
The trend of reduced GREB1 mRNA expression in the presence of 
both estradiol/icaritin compared to the cognate ligands alone mimicked the 
effect of estradiol/icaritin on MCF-7 cell proliferation.  










































Figure 3.4 Effect of estradiol and icaritin on GREB1 mRNA expression. 
MCF-7 cells were incubated with (A) indicated doses of icaritin alone or (B) 
estradiol, icaritin or 4-hydroxytamoxifen; with or without estradiol for 6 hours. 
Doses used: estradiol, 100 pM; 4-hydroxytamoxifen or icaritin, 1 µM. Total 
RNA were extracted and examined for the expression of GREB1 mRNA or 
18s rRNA. Data were normalized against time-matched DMSO and ribosomal 
18s levels, n=3, *, P < 0.05, significantly different from estradiol alone. 
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3.2.3 Estradiol/icaritin in combination induced lower ER-regulated promoter 
activity compared to either ligand alone 
Since GREB1 is an ER-regulated gene, we hypothesize that icaritin 
exerts its suppressive effects on estradiol-stimulated MCF-7 cell growth 
directly through the estrogen receptor signaling pathway. In our lab, we have 
established an ERα stable cell line, consisting of HeLa cells stably transfected 
with ERα and estrogen-driven reporter genes. This HeLa cells were used 
because of ease of transfection compared to MCF-7. ERα stable cell line was 
used to study the effect of icaritin on ERα promoter activity. The ability of 
icaritin to induce expression of luciferase reporter upon exposure was 
measured and translated into quantifiable unit using luminometer.  
The physiological estrogen, estradiol, which served as positive control, 
displayed a strong dose-dependent activation of ERE-promoter activity with 
maximal activation at 10 nM (Figure 3.5A). To facilitate comparison of ERE-
promoter activation upon icaritin treatment versus estradiol treatment, the 
result was expressed as percentage maximal estrogenic activity induced by 10 
nM estradiol. Icaritin, at doses > EC50 (0.8 µM), increased the activation of 
ERα promoter. However, the activation of ERE promoter by icaritin was weak 
because the resulting promoter activation at 10 µM icaritin was only 68% of 
10 nM estradiol. 
 Next, we tested the effect of estradiol/icaritin combination on the ERE 
activation. Icaritin was able to reduce estrogen-induced transcription at doses 
> 1 µM (Figure 3.5B). The presence of icaritin (1 µM) suppressed estrogen-
stimulated transcriptional activity by 32% to 61% and this effect could not be 
reversed by high doses of estradiol (Figure 3.5C).  
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In order to eliminate the possibility of confounding factors such as cell 
death affecting the transcriptional activity, we measured the relative cell 
number after treatments (Figure 3.5D and E). We did not find any statistical 
difference in HeLa cell number with icaritin or estradiol/icaritin treatment. 
Hence, the differential transcriptional effects induced by estradiol/icaritin were 
not due to changes in cell number. In conclusion, the presence of icaritin 
exerted a modulator effect on estrogen-stimulated ERα promoter activity and 
prevented maximal activation of the estrogen signaling pathways. 

















































































































































Figure 3.5 Effect of icaritin on ERα reporter gene assay. ERα stable cell line 
was exposed to (A) icaritin or estradiol; (B) increasing icaritin with/without 
100 pM estradiol or (C) increasing estradiol doses with/without 1 µM icaritin 
for 24 hours. Transcriptional activity was expressed as percentage maximal 
effect observed with 10 nM estradiol. All data points represented mean S.E.M. 
for triplicate readings from one representative experiment. (D and E) ERα 
stable cell lines were exposed to icaritin and/or estradiol at indicated doses and 
the cell number was measured using Cyquant™ Cell Proliferation Assay. All 
data points represented fold increase in either proliferation or transcriptional 
activity relative to the untreated (DMSO) control (mean + S.E.M., n=4). *, P < 
0.05, significantly different from estradiol or icaritin alone. 
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3.3 Icaritin as an AhR agonist 
3.3.1 Icaritin induced CYP1A1 gene expression 
Results thus far proved the estrogenicity of icaritin. However, when 
MCF-7 cells were treated with both icaritin and estradiol, icaritin decreased 
the estrogenicity of estradiol in terms of decreased MCF-7 proliferation, 
decreased GREB1 mRNA level and decreased ERE-promoter activity. To 
identify the mechanism(s) that mediate suppressive effects of icaritin on 
estradiol stimulated signaling pathways, we performed a gene expression 
microarray analysis in MCF-7 cells exposed to these ligands to identify genes 
that were differentially regulated by estradiol and icaritin.   
Inspection of heat map generated using stringent criteria (adjusted P < 
0.0001) suggested that icaritin induced a pattern of gene expression that was 
dissimilar with respect to estradiol, genistein and 4-hydroxytamoxifen. 
Although estradiol and icaritin induced generally similar gene expression 
patterns, there was one outstanding difference, CYP1A1 gene. Hierarchical 
clustering of genes placed CYP1A1 in an isolated node, indicating that 
expression profile of CYP1A1 was indeed different from other genes in this 
panel (Figure 3.6). Treatment with icaritin increased CYP1A1 mRNA level by 
5.5-fold compared to estradiol (Table 3.1), suggesting that the unique effects 
of icaritin vis a vis estradiol may be related to this gene pathway.  
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Promoter of CYP1A1 contains a xenobiotic response element (XRE) 
which is regulated by binding of activated aryl hydrocarbon receptor (AhR) 
complex (Nguyen et al, 2008; Rajaraman et al, 2009; Schrenk, 1998). Hence, 
we hypothesized that icaritin is a ligand for AhR. 
In comparison, expression profiles comparing icaritin and 4-
hydroxytamoxifen indicated that these compounds induced differential 
expression of most genes in this panel, consistent with their different effects 
on MCF-7 breast cancer cell proliferation.  







Figure 3.6 Hierarchical clustering of differentially expressed gene after 
icaritin treatment. MCF-7 cells were treated with DMSO, estradiol (10 nM); or 
4-hydroxytamoxifen, icaritin or genistein at 1 µM doses. After 6 hours, the 
cells were harvested using RNeasy Mini Kit. Biotinylated cDNA was 
generated and hybridized onto Illumina Sentrix BeadChip. Fluorescence 
detection was carried out using Illumina BeadArray Reader. Genesifter 
software was used to identify differential gene expression. Microarray data 
from triplicate experiments were subjected to ANOVA. A differentially 
regulated gene was defined as one that was activated > 2-fold and statistically 
different from the control cells treated with DMSO. Adjusted P-value  < 
0.0001. 
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Table 3.1 List of genes that are differentially regulated by icaritin treatment 
compared to estradiol and 4-hydroxytamoxifen. Microarray result for fold 
change of gene expression with estradiol or 4-hydroxytamoxifen incubation 
was shown. The list was arranged in descending numerical order based on 
icaritin/estradiol ratio. The readings were normalized against vehicle.  
 




To validate our microarray data, we performed real-time PCR on 
CYP1A1 mRNA after icaritin treatment. Since CYP1A1 is an AhR-regulated 
gene (Abdelrahim et al, 2006), an AhR agonist, 3-methylcholanthrene was 
included as positive control. As expected, 3-methylcholanthrene, the well 
known AhR agonist increased CYP1A1 mRNA level by more than 10-fold 
(Figure 3.7). Consistent with microarray data, icaritin, but not estradiol or 4-
hydroxytamoxifen, dose-dependently increased CYP1A1 mRNA expression 
(Figure 3.7). Hence, real-time PCR had successfully validated our microarray 
result, leading to conclusion that icaritin is an AhR agonist.  









Figure 3.7 Effect of icaritin on CYP1A1 gene expression. MCF-7 cells were 
treated with 100 pM estradiol; 3-methylcholanthrene (3MC), 4-
hydroxytamoxifen or icaritin at 1 µM for 6 hours. CYP1A1 mRNA levels 
were analyzed using quantitative real-time PCR. Results were normalized 
against time matched DMSO and ribosomal 18s levels. Data are mean + 
S.E.M., n = 3.    
 
Ligand 
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3.3.2 Icaritin induced AhR-regulated promoter activity  
To monitor the ligand-mediated transactivation of endogenous 
receptors, a luciferase reporter plasmid bearing AhR consensus binding 
elements XRE was transiently transfected into MCF-7 cells. The transfection 
efficiency and cell viability was normalized against readings from Renilla 
luciferase control reporter that was co-transfected into the cells.  
Figure 3.8 showed that 3-methylcholanthrene and icaritin activated the 
transcriptional activity of XRE with EC50 of 2.7 µM and 6.8 µM respectively. 
10 µM of icaritin and 0.1 µM of 3-methylcholanthrene increased the 
transcriptional activity of XRE respectively. At the same dose, MCF-7 
proliferation decreased in the presence of icaritin (Figure 3.1A). Since 3-
methylcholanthrene also activates transcription of XRE, there is a possibility 
that 3-methylcholanthrene could also modulate MCF-7 cells growth stimulated 
by estradiol. Moreover, published data have also showed that AhR agonists 
such as 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and the non-ortho-
substituted polychlorinated biphenyl (PCB) inhibited breast cancer cell 
proliferation in vitro (Oenga et al, 2004). The doses of icaritin which inhibited 
estradiol-stimulated breast cancer cell proliferation coincided with its activity 
on AhR signaling. Based on the above, we hypothesized icaritin-activated 
AhR may play a part in decreased MCF-7 growth when the cells were treated 
with combination of estradiol and icaritin. 
 








































Figure 3.8 Effect of icaritin on XRE reporter gene assay. MCF-7 cells were 
transiently transfected with pXRE-Luc and Renilla. The cells were exposed to 
increasing doses of icaritin or 3-methylcholanthrene. Transcriptional activity 
was expressed as percentage maximal effect observed with 10 µM 3-
methylcholanthrene. Transfection efficiency was normalized using Renilla 
control reporter. All data points represented fold increase in transcriptional 
activity relative to the untreated (DMSO) control (mean + S.E.M., n=4).  
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3.3.3 Icaritin bound directly to AhR  
We further confirmed the role of icaritin as an AhR agonist by 
competitive binding assay in the presence of [3H]-TCDD. We collaborated 
with Dr. Denison’s lab of University of California, USA for this experiment 
because they had an established method for AhR competitive binding assay.  
The results from competitive binding assays indicated that icaritin was 
a bona-fide AhR ligand and specific [3H]-TCDD binding was completely 
inhibited by 1 × 10-5 M of icaritin (Figure 3.9). IC50 of known AhR agonist, 
2,3,7,8-tetrachlorodibenzofuran (TCDF) binding to AhR in competitive 
binding assay was approximately 1000 times lower, 1 × 10-9 M (Bohonowych 
et al, 2007). Hence, icaritin is an AhR agonist. 


































Figure 3.9 Competitive binding of icaritin to AhR. Experiments are conducted 
by Dr Denison, University of California. Hepatic cytosol from male C57BL/6 
mice was incubated with 2 nM [3H]-2,3,7,8-tetrachlorodibenzo-p-dioxin ([3H]-
TCDD) in the presence of DMSO (1%), 2,3,7,8-tetrachlorodibenzofuran 
(TCDF; 200 nM), or increasing concentrations of icaritin for 2 hours in a room 
temperature water bath.  [3H]-TCDD binding was determined by HAP 
binding. The total amount of [3H]-TCDD specific binding was obtained by 
subtracting the non-specific binding ([3H]-TCDD and TCDF) from the total 
binding [3H]-TCDD.   
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3.4 Estradiol/icaritin in combination destabilized ERα protein 
more than either ligand alone 
One of the most important etiologies for breast cancer proliferation is 
hormonal control of its growth via ERα. MCF-7 cells with stable knockdown 
of ERα exhibited suppression in proliferation and enhanced apoptosis (Fu et 
al, 2006). Hence, we proceeded to check the expression level of ERα after 
treatment to check the involvement of ERα in estradiol/icaritin mediated cell 
proliferation.  
AhR has been shown to promote proteolysis of ERα through assembly 
of a ERα-specific ubiquitin ligase complex, CUL4-BAHR (Ohtake et al, 2007; 
Ohtake et al, 2009).  This action defines the role of AhR as a ligand-dependent 
E3 ubiquitin ligase. To explore the concept that suppressive effects of icaritin 
on estradiol-stimulated MCF-7 cell proliferation may be related to AhR-
directed proteolysis of ERα, we examined the effect of icaritin on ERα protein 
stability with immunoblotting. Icaritin dose-dependently destabilized ERα 
protein levels (Figure 3.10A). Unlike 4-hydroxytamoxifen which increased 
ERα protein levels, icaritin and estradiol both reduced the ERα protein levels 
(Figure 3.10 B). The most striking effect on ERα stability was observed with 
the estradiol/icaritin combination. The presence of estradiol/icaritin in 
combination resulted in 83% and 68% lower ERα protein levels compared to 
the individual effects of estradiol and icaritin respectively (Figure 3.10B). This 
implied synergistic effect of icaritin and estradiol in degrading ERα. 
Destabilization of ERα in the presence of estradiol and icaritin was 
partially reversed by addition of proteasome inhibitor MG132 (Figure 3.10B), 
suggesting that these changes were mediated through the proteasomal 
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pathway. These effects could not be attributed to changes in ERα mRNA 
levels (Figure 3.10E). The additional effect of icaritin on ERα stability in the 
presence of estradiol was dose-dependent (Figure 3.10C), consistent with its 
suppressive effects on the estradiol-stimulated growth of these breast cancer 
cells. 
To test whether AhR directly affected ERα stability, we performed 
experiments whereby AhR was silenced using RNA interference. Transfection 
of specific small interfering RNA against AhR (siAhR) reduced expression of 
AhR mRNA by over 85% at 24 to 48 hours time points compared to cells 
expressing a scrambled siRNA sequence (Figure 3.10 F). MCF-7 cells were 
transformed with siAhR and treated with icaritin and estradiol (Figure 3.10D). 
Knockdown of AhR gene induced a partial rebound in ERα (Figure 3.10D), 
congruent with the observation that AhR mediated this action of icaritin. In 
contrast, knockdown of AhR gene did not restore estradiol-mediated 
degradation of ERα because estradiol did not bind AhR (Ohtake et al, 2003). 
Most strikingly, MCF-7 cells exposed to both estradiol and icaritin showed a 
complete destabilization of ERα protein and this ERα destabilization was 
blocked by AhR knockdown (Figure 3.10D).   
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Figure 3.10 Western blotting for ERα protein stability. MCF-7 cells were 
cultured for 24 hours with the indicated ligands, alone or in combination with 
estradiol. Protein was extracted from whole cell lysates and probed with 
specific antibodies to ERα or β-actin. The intensity of ERα signal was 
measured by ImageJ and normalized to β-actin. (A) Icaritin, 0.01-10 µM; 
estradiol, 100 pM; (B) 4-hydroxytamoxifen, 1 µM; icaritin, 1 µM; estradiol, 
100 pM; MG132, 20 µM. ERα-negative MDA cells were used as negative 
control. (C) icaritin (0.01-1 µM) and/or estradiol (100 pM). (D) Cells were 
transfected with siAhR or siScrambled. Doses used: icaritin, 1 µM; estradiol, 
100 pM. Representative blots were shown. Data are mean + S.E.M., n=3. (E 
and F) Total RNA were extracted and examined for the expression of GREB1 
mRNA and 18s rRNA via real-time PCR. Data were normalized against time-
matched DMSO and ribosomal 18s levels, n=3. 
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3.5 AhR knockdown reversed icaritin modulation of estradiol 
stimulated MCF-7 cell proliferation 
To test whether AhR activity affected breast cancer cell growth, we 
performed experiments whereby AhR was silenced using RNA interference, as 
per section 3.4. Growth patterns of MCF-7 cells transfected with siRNA 
against AhR were compared to cells transfected with scrambled siRNA 
sequence. As expected, icaritin suppressed estradiol-stimulated cell growth in 
cells with AhR knockdown (Figure 3.11A). In contrast, cells transfected with 
siAhR reversed the suppressive effects of icaritin on the growth of estradiol-
stimulated MCF-7 cell growth. Additionally siAhR reversed the suppressive 
effect of high doses of icaritin alone (Figure 3.11 B); an effect not observed 
with estradiol (Figure 3.11C). Similarly silencing of AhR resulted in reversal 
of the inhibitory effect of icaritin on estradiol-stimulated GREB1 mRNA 
expression (Figure 3.11D). Overall, our data indicated the suppressive effect 
of 1 µM icaritin on estradiol-stimulated cell growth and GREB1 gene 
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Figure 3.11 Effect of AhR knockdown on MCF-7 cell proliferation and 
GREB1 expression. (A, B, C) Cell proliferation studies. Growth effects of 
icaritin and estradiol, alone or in combination, on MCF-7 cells whose AhR 
was silenced (siAhR) was compared to cells transfected with a random siRNA 
sequence (siScrambled). Cell proliferation was measured using Cyquant™ 
Cell Proliferation Assay. All data points represented the fold increase in cell 
number over vehicle (mean + S.E.M., n=4). *P < 0.05, comparing cells with 
or without AhR knockdown. (D) GREB1 mRNA expression. Cells were 
transiently transfected with the indicated siRNA for 24 hours and incubated 
with icaritin (1 µM) and/or estradiol (100 pM). GREB1 mRNA level was 
measured using real-time PCR. Results were normalized against time matched 
DMSO and ribosomal 18s levels. Data are mean + S.E.M. for triplicate 
amplification reactions from one representative experiment, n = 3. *, P < 0.05. 
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CHAPTER 4 DISCUSSION 
Here we identify a novel mechanism whereby, icaritin, restricts 
estradiol-stimulated breast cancer cell growth by activating AhR pathways. 
Acting synergistically with estradiol-mediated degradation pathways, 
activation of AhR resulted in profound destabilization of ERα protein, leading 
to inhibition of estrogen-regulated MCF-7 breast cancer cell growth and 
GREB1 gene expression. Repeated experiments indicate their combinatory 
effects on MCF-7 cell proliferation were lower than that observed for either 
ligand alone. At low doses of icaritin, estrogenic stimulation predominates as 
sufficient ERα protein is present for estrogenic drive to be exerted, thereby 
increasing cell proliferation. The proliferative effect of icaritin on MCF-7 cells 
at low dose is in agreement with previously published data (Wang et al, 2004). 
Unlike the data from Wang et al, we found that icaritin decreased MCF-7 
proliferation at 10 µM.  
Combination of icaritin and estradiol decreases estrogenic drive and 
MCF-7 proliferation as the ERα protein is reduced to undetectable levels 
(Figure 3.10B). This subsequently suppressed the expression of GREB1 
(Figure 3.4B), an endogenous ERα-regulated gene implicated in the growth of 
breast cancer cells (Rae et al, 2005). Although a bona-fide estrogenic ligand 
on its own, icaritin suppressed estradiol-stimulated GREB1 gene expression to 
a degree exceeding that observed with the anti-breast cancer compound, 4-
hydroxytamoxifen (Figure 3.4B). This suppressive effect was associated with 
reduced ER-regulated promoter activity, suggesting that the reduction of 
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estrogenic drive may be a contributory factor to inhibition of MCF-7 
proliferation.  
Using a genomic approach to identify genes that mediate these effects, 
we determined CYP1A1 to be the genetic pathway most differentially affected 
by icaritin compared to other tested compounds. Expression of CYP1A1 is 
mainly regulated by AhR/ARNT acting though multiple consensus xenobiotic 
response elements in the CYP1A1 promoter (Ma, 2001). Quantitative real-
time PCR and reporter assays driven by the AhR-driven xenobiotic response 
element confirmed that icaritin was an AhR ligase, promoting proteasomal 
degradation of ERα through targeted assembly of the ubiquitin ligase complex, 
CUL4BAhR (Ohtake et al, 2007; Ohtake et al, 2003). This concept was 
supported by experimental data indicating that icaritin dose-dependently 
destabilized ERα protein. Since estradiol itself can also induce ERα 
degradation through specific proteasome-mediated pathways (Shao et al, 
2004), the combined effects of estradiol-ERα and icaritin-AhR led to complete 
degradation of ERα protein (Figure 3.10B and D). Synergistic destabilization 
of ERα by the estradiol/icaritin combination was reversed if AhR was 
silenced. Silencing of AhR abolished the restrictive effect of icaritin on 
estradiol-stimulated breast cancer cell growth and gene expression, suggesting 
a mechanistic role for AhR in this phenomenon (Figure 3.11A). In 
comparison, transfection with siAhR did not reduce estradiol-induced cell 
proliferation or gene expression (Figure 3.11C). Overall, our data support a 
model in which icaritin, through specific AhR-directed proteasomal 
degradation, leads to synergistic degradation of ERα protein, thereby 
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restricting estradiol-stimulated MCF-7 cell growth and GREB1 gene 
expression.  
In conjunction to report that proteolysis was modulated by ligand 
concentration (Preisler-Mashek et al, 2002), various doses of icaritin were 
tested in our study to allow for quantitative analysis of changes in ERα level. 
Indeed, we see a dose dependent decrease in ERα protein with icaritin 
treatment. Our data supports the proteasome-mediated degradation of ERα 
since the presence of proteasome inhibitor, MG132, partially reversed the ERα 
degradation induced by estradiol/icaritin.  
Ligands which are dual activators for ERα and AhR mechanistically 
represent a new class of selective estrogen receptor modulators (SERMS). Our 
study suggests a critical role for ERα stability in estrogen modulator activities 
of various SERMS. Although ERα degradation requires the proteasome as the 
ultimate step, recent findings suggest that SERM binding to ERα initiate 
distinct pathways that differentially affect ERα stability. For example, 
estradiol and fulvestrant treatment results in degradation of ERα whereas 4-
hydroxytamoxifen stabilizes the receptor (Calligé et al, 2006).  
Molecular mechanisms leading to ERα degradation is ligand 
dependent. However, cellular levels of ERα are maintained by distinct 
receptor degradation pathways that ultimately converge on the ubiquitin 26S 
proteasome system. For example, in the absence of ligand, co-chaperone 
ubiquitin ligase carboxy terminus Hsc70-interacting protein (CHIP) is an E3-
ubiquitin ligase required for basal ERα ubiquitination and proteasomal 
degradation (Tateishi et al, 2004). The degradation is slow, partly due to the 
presence of lysine 302/303 which stabilizes unliganded ERα by decreasing 
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polyubiquitination through reducing association of CHIP and Bag1 
Complexes. Upon binding of agonist such as estradiol, chaperone proteins are 
released and transcription-dependent degradation takes place (Berry et al, 
2008).  
In the presence of estradiol, the transcriptional machinery is tightly 
coupled to the proteasomal degradation of ERα. The co-activator, SRC3, 
uniquely mediates estradiol-induced ERα degradation (Chu et al, 2007; Shao 
et al, 2004). A catalytic subunit of the 20S proteasome (LMP2) is recruited to 
and interacts with SRC3 in the transcriptionally active, estrogen-regulated 
promoters (Zhang et al, 2006). Suppression of SRC3, by siRNA leads to 
stabilization of ERα. SRC3 interacts with the ubiquitin ligase E6-associated 
protein (E6-AP) to degrade tumor suppressor p53. However, E6-AP is not the 
sole factor mediating estradiol bound ERα degradation, as silencing of E6-AP 
did not stabilize the receptor. The control of estradiol bound ERα degradation 
is indirect and can be mediated through degradation of SRC3 by a distinct 11s 
particle, a non-ATP REGγ linked to 20S proteasome cap (Li et al, 2006).   
The steroidal anti-estrogen ICI 182, 780 (also known as fulvestrant or 
Faslodex) with long bulky side chain was recently approved for treatment of 
metastatic cancer. Unlike estradiol, presence of fulvestrant leads to 
degradation of ERα via a pathway that is independent of SRC3 mediated-
transcriptional and protein synthesis pathway. Silencing of SRC3 did not 
block fulvestrant mediated ERα degradation (Shao et al, 2004). The 
compartment in which ERα is degraded may also result in different 
mechanism for degradation. Fulvestrant bound ERα is degraded in the nucleus 
whereas estradiol bound ERα occurs in the cytoplasmic fractions (Calligé et 
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al, 2006). Fulvestrant bound ERα binds to two intermediate filament proteins, 
cytokeratins 8 and 18 (CK8 and CK 18), found in both cytoplasm and nucleus. 
Fulvestrant–ERα complex is detected in both nucleus and cytoplasm, but 
fluorescence/photobleaching studies indicate that nuclear mobility is reduced 
with sequestration of the receptor in the salt insoluble nuclear compartment 
(Long et al, 2006). On top of that, proteasomes have been shown to be 
associated primarily with intermediate filaments. Hence, it is not a surprise 
that CK8- and CK-18 negative cancer cells did not exhibit fulvestrant induced 
receptor degradation (Long et al, 2006), leading to the conclusion that 
fulvestrant mediated ERα degradation requires CK8 and CK-18 intermediate 
filaments. There is also evidence that fulvestrant elicits an unusual 
organization of the receptor ligand-binding domain and may be recognized by 
the cell as a misfolded protein, targeting it for destruction (Fan et al, 2003).  
On the other hand, partial antagonist tamoxifen stabilizes ERα and 
prevents ERα degradation without activating the receptor (Laïos et al, 2005). 
The prevailing hypothesis attributes the ERα stabilization effect of tamoxifen 
to displacement of helix 12 of the liganded-ERα leading to preferential 
recruitment of co-repressor molecules that do not activate proteasomal-
mediated degradation of the receptor (Kong et al, 2003). Tamoxifen bound 
ERα is exclusively nuclear (Long et al, 2006). 
AhR is expressed in tissues from normal and cancerous breasts (Hall et 
al, 2010). Although evolutionarily and structurally dissimilar to the steroid 
hormone receptor family, AhR is the only known ligand-activated member of 
the basic helix-loop-helix/PAS family of transcription factors.  There is 
increasing evidence that the AhR signaling intersects with ER function. AhR 
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forms atypical ubiquitin-ligase enzymes that specifically mark estradiol bound 
ERα for degradation (Ohtake et al, 2007). Targeted disruption of AhR in 
mouse results in altered ovarian follicle (Baba et al, 2005) and mammary 
development (Hushka et al, 1998). Recent study of an in vitro model of human 
breast cancer cell invasiveness indicate that ligand-activated AhR can inhibit 
cellular motility and promote expression of markers for cell differentiation 
(Hall et al, 2010). Knockdown of AhR reverses these effects (Hall et al, 
2010). In both in vitro and in vivo models, dioxins were able to reverse the 
proliferative effects of estrogens (Oenga et al, 2004), likely through their 
ability to degrade ERα protein (Wormke et al, 2003). 
Recently, 4-hydroxytamoxifen has been described to bind and activate 
AhR–regulated genes such as CYP1A1, in breast cancer cells (DuSell et al, 
2010). Our microarray analysis (Figure 3.6) and subsequent quantitative real-
time PCR (Figure 3.7) did not support this conclusion as exposure to 4-
hydroxytamoxifen for 6 hours did not change CYP1A1 gene expression. 
Moreover ERα was stabilized and not degraded, as might be expected if AhR 
was activated. 
Based on studies on 2,3,7,8-tetrachlorodibenzofuran (TCDD), a well-
known AhR agonist, we postulated that there are several mechanisms by 
which icaritin affects MCF-7 cell proliferation. Among the possible 
mechanisms are inhibition of the G0/G1 to S cell cycle progression 
(Abdelrahim et al, 2003); and downregulation of mRNA for the G-protein-
coupled receptor, CXCR4 and its chemokine, CXCL12 (Hsu et al, 2007). 
However, experiments are needed to determine whether these mechanisms 
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participate in distinct or overlapping signaling pathways to collectively 
modulate ERα stability in the presence of icaritin.  
Interestingly it was also observed that combination of estradiol and 
TCDD inhibited ERα protein more than either estradiol or TCDD alone. 
Administration of TCDD can result in suppression of estradiol-dependent 
growth of xenotransplanted MCF-7 breast cancer cell (Gierthy et al, 1993).  
However polyhalogenated hydrocarbons such as TCDD and other 
dioxins might be unsuitable as anti-cancer agents because epidemiological 
studies indicate that occupational exposures to TCDD are associated with an 
increased risk for all combined cancers  (McGregor et al, 1998). AhR ligands 
are reported to be highly embryotoxic and cause hyperplasia of the epithelium 
of the stomach, intestines and urinary bladder (Poland et al, 1982). On the 
other hand, populations exposed to dioxins exhibit a decrease in incidence of 
estrogen-driven invasive breast cancer (Viel et al, 2008) and endometrial 
cancers (Bertazzi et al, 1997).   
 We need to bear in mind the multi-faceted role of AhR agonist in 
stimulation/inhibition of cancer growth. For instance, AhR agonist induces 
transcription of drug metabolizing enzymes CYP1A1 enzyme that could 
metabolize pro-carcinogens into ultimate carcinogens (Androutsopoulos et al, 
2009). When the balance of the process is tipped towards ultimate carcinogens 
production, cancer growth will be stimulated. Also, considering the cell 
dependent potencies of AhR agonists (Zhang et al, 2003), the effect of icaritin 
on different cancer types need to be studied as some AhR agonist are reported 
to activate AhR in one cell type but not the other. This information is essential 
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to avoid development of another selective estrogen receptor modulator 
(SERM)-like compound for breast cancer treatment.  
  This study indicates that there are three classes of selective AhR 
modulators (sAhRMs), classified according to their binding to AhR and ERα. 
This can be further refined to the effect of the ligand on ERα stability upon 
receptor binding. The classes are 1) dioxin-like compounds such as TCDD 
which does not bind ERα but bind and activate AhR to degrade ERα receptor; 
2) compounds such as 4-hydroxytamoxifen which is ERα antagonist but an 
AhR agonist (DuSell et al, 2010) and stabilizes ERα protein; and 3) 
compounds such as icaritin which is both ERα and AhR agonist but degrades 
ERα protein. Given the current challenges in treating metastatic breast cancer, 
the clinical development of sAHRMs may provide an effective, broad-based 
alternative to current adjuvant therapies.  
Prior to this report, the mechanism of flavonoid reduction of estradiol-
stimulated MCF-7 cell growth was unknown. We have shown that the 
mechanism is via AhR-mediated pathway. Our data showed that 
estradiol/icaritin combination was unable to induce maximal MCF-7 cell 
proliferation due to total degradation of ERα. We propose that icaritin-
activated AhR induces polyubiquitination, recruitment and assembly of 
CUL4B-AhR complex that synertistically targets the ERα for proteasomal-
mediated degradation in the presence of estradiol (Figure 4.1). This finding 
may have implications for cancer growth and therapy. If the icaritin’s 
modulatory action on estradiol stimulated MCF-7 cell growth can also be 
proven in vivo, we propose that icaritin could be given in conjunction with 
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hormone replacement therapy (HRT) to modulate the increase in breast cancer 
risk due to HRT.   








Figure 4.1  Crosstalk between icaritin and estradiol signaling pathways 
through AhR-directed proteasomal degradation. In the classical estradiol-
mediated ERα degradation pathway, estradiol-bound ERα undergo ubiquitin 
ligase mediated degradation after initiating gene transcription. In the presence 
of icaritin and estradiol, icaritin binding to AhR activates CUL4B ubiquitin 
ligase complex that synergistically degrades ERα in the presence of estradiol. 
This profound degradation of ERα in the presence of both icaritin and 
estradiol leads to suppressive effect of icaritin on estradiol-stimulated growth 
of MCF-7 cells in vitro. 
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